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General background 
1. Gatrointestinal stromal tumor 
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the 
gastrointestinal (GI) tract [1]. For decades, prior to the 1990s, these mesenchymal tumors arising in 
the GI tract were often classified as smooth muscle tumors or neural tumors [2]. In 1983, Mazur and 
Clark introduced the term “stromal tumor”, but it was not broadly accepted until the early 1990s, 
when CD34 was discovered as a marker for stromal tumors growing in the GI tract [3-4]. 
In the 1990s, investigators noted similarities between GIST cells and the interstitial cells of Cajal 
(ICC), a group of cells located in the musculature and around the myenteric plexus throughout the 
GI tract, working as pacemakers for peristaltic contraction. Further studies revealed that ICC 
express KIT and are developmentally dependent on stem cell factor (SCF) [5-7]. In 1998, a 
revolutionary publication by Hirota and colleagues, showed activating mutations in the KIT 
receptor tyrosine kinase (RTK) gene in GISTs as well as expression of KIT protein by 
immunohistochemistry [6]. In 2003, Heinrich and colleagues additionally identified platelet-derived 
growth factor receptor alpha (PDGFRA) gene mutations, as an alternative pathogenetic event in 
GISTs lacking KIT gene mutations [8]. To date, approximately 85% of GISTs are reported to 
harbor activating mutations in KIT or the homologous RTK gene, PDGFRA [8–11]. 
1.1 Oncogenic KIT and PDGFRA mutations and signaling pathways in GIST 
The KIT and PDGFRA genes map to chromosome 4q12. Both encode type III receptor tyrosine 
kinases with closely related structural features. These kinases are constituted by an extracellular 
(EC) ligand-binding domain containing five immunoglobulin-like repeats, a transmembrane 
sequence, a juxtamembrane domain (JM), and two cytoplasmic kinase domains (TK[I]: ATP-
binding pocket and TK[II]: kinase activation loop, Figure. 1) [11-12]. 
KIT and PDGFRA are activated by binding of their ligands, SCF and PDGFA respectively, to the 
EC domain. Ligand binding brings to the receptor homodimerization and subsequent cross-
phosphorylation of cytoplasmic tyrosines, which operate as binding sites for various signalling 
proteins: KIT and PDGFRA tyrosine kinase activity is regulated by phosphorylation cascades with 
activation of signaling substrates regulating cell proliferation, adhesion, motility, and survival [13]. 
On the whole, KIT and PDGFRA activation regulates important cell functions including 
proliferation, apoptosis, adhesion, and chemotaxis (Figure 1) [13-14]. In addition it is critical for the 
development and maintenance of several cell types, as well as hematopoietic cells, ICC, germ cells,  
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mast cells, and melanocytes [13-14]. Mutations in KIT or PDGFRA gene involve two main regions, 
the receptor regulatory domains (dimerization region in the EC and JM domains) and the enzymatic 
domains (TK[I] and TK[II]). In GISTs most KIT mutations (?65%) involve the JM domain (exon 
11) followed by mutations involving the EC dimerization domain (exon 9) which are seen in about 
9% of cases. Primary KIT mutations can also occur in exon 13 (TK [I) and exon 17 (TK[II]), but 
these mutations are rare events (?2%) and data are quite limited (Figure 2). 
Figure 1. Oncogenic signaling in KIT and PDGFRA 
GISTs dimerization of KIT and PDGFRA leads to 
phosphorylation of tyrosine residues and the activation of 
different pathways, including RAS/RAF/MEK and 
PI3K/AKT/mTOR. RAS (green cascade) activates the 
MAPK cascade (RAF, MEK and ERK), and stabilizes 
ETV1 expression, leading to changes in gene expression. 
In wild-type GIST, mutation in NF1 (light blue), RAS or 
BRAF can all activate the signaling through the MAPK 
cascade. PI3K (red cascade) activates the mTOR pathway 
that leads to alteration in protein translation and cell 
survival. In wild-type GISTs, mutation in RAS may 
activate the PI3K cascade, as well. Phosphorylation of JAK 
leads to STAT3 activation (orange cascade), which 
promotes JUN transcription, important for cell 
proliferation and survival. Wild-type GISTs show high 
expression of IGF1R (purple cascade), which signals 
through both the MAPK and the PI3K pathways. Recently, 
defects in SDH have been identified in wild-type GIST, 
(gray cascade). Loss-of-function mutation in any of the 
SDH subunits leads to cytoplasmic accumulation of 
succinate, which downregulates prolyl hydroxylase. In 
turn, prolyl hydroxylase promotes proteasomal degradation 
of HIF1. Therefore, succinate cytoplasmatic accumulation 
leads to increased levels of HIF1, which enters the 
nucleus and activates, among others, the transcription of 
the VEGF gene.
Figure 2. Kit mutations in untreated GISTs in exon 9, 11, 
13 and 17, encoding part of the EC and JM domains, 
respectively. PDGFRA mutations, found in <10% of 
GISTs, involve the same domains.
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1.2 Epidemiology, clinical features and prognosis of GISTs. 
The exact incidence of GIST in the USA and Europe is very difficult to estimate, since GISTs have 
only been properly recognized and uniformly diagnosed as an entity starting only in late 1990s. 
Recent population-based studies performed in Sweden [14], Holland [15] and Iceland [16] found 
incidences of approximately 14.5, 12.7, and 11 cases/million per year, respectively. These findings 
would translate into an annual incidence in Europe of ?8,000-9,000 cases and in the USA of ?
4,000-5,000 cases a year. 
GIST patients range in age from the teens to the 90s, but peak age is around 60 years. The tumors 
are generally between 2 and 30 cm in diameter at the time of diagnosis and may cause mass-related 
symptoms or anemia as a result of mucosal ulceration. Not infrequently, however, GISTs are 
discovered incidentally during radiologic imaging for unrelated conditions, or as a secondary 
finding in a surgical resection or autopsy specimen [18]. 
GISTs occur throughout the entire GI tract and are most commonly found in the stomach (60%), 
jejunum and ileum (30%), duodenum (5%), colorectum (4%), and rarely in the esophagus and 
appendix [1,4,17]. Clinical symptoms associated with GIST include abdominal pain, fatigue, 
dysphagia, obstruction and satiety. Patients may suffer of with chronic GI bleeding (causing 
anemia) or acute GI bleeding (caused by erosion through the gastric or bowel mucosa) or rupture 
into the abdominal cavity causing life-threatening intra-peritoneal hemorrhage. Previously, a 
population-based study revealed that about 70% of GISTs were associated with clinical symptoms, 
20% were not, and 10% were detected at autopsy [19]. 
1.3 Histopathology
Morphologically, GISTs can have three main histological subtypes: I) spindle cell type (accounting 
70% of the cases), II) epithelioid type (20-25%), and III) mixed spindle cell and epithelioid type 
(10%) (Figure 3). In general, GISTs have a wide variation ranging from hypocellular to highly 
cellular with higher mitotic rates.  
Spindle cell type of GIST is made up of cells in short fascicles. They have clear eosinophilic 
fibrillary cytoplasm, ovoid nuclei, and ill-defined cell borders. Gastric spindle cell GISTs often 
reveal extensive perinuclear vacuolization, a diagnostic feature formerly used for tumors of smooth 
muscle origin. Distinctive histological patterns among spindle cell GISTs including sclerosing type 
and vacuolated type [1].  
Epithelioid cell GISTs are characterized by round cells arranged in nests or sheets and with 
eosinophilic to clear cytoplasm. 
Finally, approximately 10% of GISTs show mixed morphology, being composed of both spindle 
and epithelioid cells [1]. 
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1.4 Wild-type GIST 
About 85% of paediatric GIST and about 10–15% of adult GISTs do not harbour any mutations in 
the KIT and PDGFRA genes and are deﬁned as KIT/PDGFRA wild type (WT) [10]. 
WT GIST occur more often in women, often arise from the stomach, are multifocal, have a frequent 
epithelioid morphology and show an indolent course even if metastatic on diagnosis [20,21]. 
KIT/PDGFRA WT GISTs represent a highly heterogeneous group of patients, profoundly different 
from mutant tumors in their genomic background. About 50% of KIT/PDGFRA WT GISTs present 
an overexpression of insulin-like growth factor 1 receptor (IGF1R) at the mRNA and protein level 
[22,23]. Differences in the expression of genes that belong to neural tissue were also seen between 
tissue from mutated GIST and murine mature ICC, suggesting that KIT/PDGFRA WT GIST may 
have a different origin [24]. Furthermore, in KIT/PDGFRA WT GIST, several mutations have been 
described with uncertain pathogenic significance. In particular, BRAF exon 15 V600E substitution 
is present in up to 13% of GISTs [25]. In the past years interesting data on succinate dehydrogenase 
(SDH) complex deficiency in KIT/PDGFRA WT GIST, have also emerged, delineating a small 
group of GISTs with peculiar clinical and molecular features [26,27]. 
SDH complex, or mitochondrial complex type II, represents one of the five complexes belonging to 
the mitochondrial respiratory chain and is involved in the Krebs cycle and electron transport of 
oxidative phosphorylation. It shows a tetrameric structure composed of two hydrophilic subunits 
Figure 3. a GIST composed of spindle cells with 
uniform ovoid or a GIST composed of spindle 
cells with uniform ovoid or defined cell borders. 
b GIST composed of epithelioid cells 
witheosinophilic or clear cytoplasm. c GIST 
with mixed spindle cell and epithelioid 
cytomorphology. 
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with catalytic activity (SDHA and SDHB) and two hydrophobic subunits linked to the inner 
mitochondrial membrane (SDHC and SDHD). Germline or somatic inactivating SDH-inactivating 
mutations have been described in several tumours, such as paragangliomas / pheocromocitomas and 
renal-cell carcinoma [26-28]. 
The first evidence of germline SDHB- and SDHC-inactivating mutations in sporadic KIT/PDGFRA 
WT GISTs was reported in 2011 as ‘type 2 GIST’ [26]. Despite the low incidence of SDH-
inactivating mutations, it has been reported that about 5–7.5% of sporadic KIT/PDGFRA WT 
GISTs show negative immunohistochemistry staining of SDHB [28]. SDH-deficient GIST comprise 
the great majority of gastric GISTs in children and young adults and a small proportion of gastric 
GISTs in older adults displaying a distinct clinical and pathological phenotype with respect to 
KIT/PDGFRA mutant GISTs. 
1.5 Familial GIST 
Several progenies with heriTable mutations in the juxtamembrane domain (exon 11) of the KIT 
gene have been identified. The first to be reported was a Japanese family in which a deletion of one 
of two consecutive valine residues (codon 559 or 560, GTTGTT) was traced through three 
generations. Affected individuals had hyperpigmentation of perineal skin and suffered the 
development of multiple benign and malignant GISTs [29]. A germline V559A substitution has 
been described in an italian family and in another one from Japan [30,31]. Affected members in 
both progenies had pigmented macules involving the skin of the perineum, axilla, hands, and face 
(with the exception of lips and buccal mucosa), as well as evidence of skin mastocytosis (urticaria 
pigmentosa) on biopsy. In addition, patients in both families developed multiple GISTs in the 
stomach and small bowel as early as age 18 years. A germline mutation in the kinase I domain of 
KIT was reported in a 67-year-old mother and her 40-year-old son from France. Both patients had 
more than a dozen of duodenal and jejunal GISTs, and both were found to have a constitutional 
K642E substitution in exon 13 of the KIT gene [32]. A mutation in the activation loop of KIT has 
been recently described by Hirota et al in a kindred with multiple gastric and small bowel GISTs 
[33]. The D820Y mutation found in affected family members caused diffuse ICC hyperplasia and 
GIST formation but was not associated with skin hyperpigmentation or mast cell disease.  
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2. Treatment of GIST 
Important improvements have occurred in GISTs treatment in recent decades. Before 1990s, GISTs 
have been erroneously diagnosed as smooth-muscle tumors of the GI tract such as 
leiomyoblastomas and leiomyomas. Due to the wrong diagnosis GISTs erroneously were 
unsuccessfully treated with radiotherapy and conventional chemotherapy as mesenchymal 
neoplasms [34,35]. When it was clear that GISTs were a distinct tumor, the paradigm of GIST 
treatment has dramatically changed. Currently, GIST has been changed from an incurable disease to 
a manageable, chronic condition for a significant proportion of patients [36]. 
The two gold standards of GISTs treatment are surgery and imatinib. Complete surgical removal is 
the standard therapy for localized resecTable GIST; in locally advanced and metastatic GIST 
imatinib is the first choice drug 
2.1 Imatinib 
The initial pilot study of imatinib in advanced GIST occurred in the year 2000 with a Finnish 
patient with metastases to the peritoneum and liver which progressed despite multiple lines of 
chemotherapy [36]. With a 400 mg/daily dose, after 8 months of treatment, six of twenty-eight liver 
metastases were no longer detecTable. The successful treatment of the first patient with metastatic 
GIST set off a fast succession of pivotal trials. 
Imatinib mesylate (GLEEVEC
®
 formerly STI571, Novartis Pharma AG, Basel, Switzerland) is a 
tyrosine kinase inhibitor (TKI) with activity against ABL, BCR-ABL, KIT, PDGFRA, PDGFRB 
and CSF1R. Its structure mimics adenosine triphosphate (ATP) and it binds competitively to the 
ATP binding site of the target kinases. 
This prevents substrate phosphorylation 
and signaling, thereby inhibiting 
proliferation and survival [38, 39] 
(Figure 4). 
Two important observations made in 
1999 suggested that imatinib might be 
effective against GISTs. The first was 
that imatinib could block the in vitro
kinase activity of both wild-type KIT 
and a mutant KIT isoform commonly 
found in GISTs (point mutation in exon 11) [40]. The second observation was that imatinib 
Figure 4. Mechanism of imatinib action 
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inhibited the growth of a GIST cell line containing a KIT gene mutation [41]. In part, on the basis of 
these preclinical findings, a patient with GIST with metastasis to the liver was granted 
compassionate use of imatinib mesylate in March 2000 [37]. The success in treating the first GIST 
patient with imatinib quickly led to a multicenter trial (CSTIB2222) that involved the Dana-Farber 
Cancer Institute, Fox-Chase Cancer Center, Oregon Health & Science University Cancer Institute, 
and the University of Helsinki [42]. In this trial, 147 patients with advanced, unresecTable, KIT-
positive GIST were enrolled. Patients were randomly assigned to either 400 mg or 600 mg per day 
in a single oral dose. With a follow-up of at least 6 months, partial responses were observed in 54% 
of patients, and an additional 28% had sTable disease. Disease progression was seen in only 14% of 
patients during initial follow-up. Similar results were reported for the European Organization for 
Research and Treatment of Cancer Soft Tissue and Sarcoma Group phase I study of imatinib for 
patients with advanced soft tissue sarcomas, including GISTs [42]. On the basis of the results of the 
CSTIB2222 trial and the European Organization for Research and Treatment (EORTC) of Cancer 
trial, IM was approved by the US Food and Drug Administration, FDA, for the treatment of 
unresecTable and metastatic GIST on February 1
st
, 2002. 
2.1.1 Correlation between KIT and PDGRFA mutation status and imatinib response 
The presence and the type of KIT or PDGFRA mutation status are predictive of outcome to 
imatinib. Exon 11 mutations occur in the KIT juxtamembrane domain and are the most common 
mutations in GISTs. Tumors with exon 11 mutations have better response rates to imatinib, with a 
longer progression free survival (PFS) and overall survival (OS). Exon 9 mutations, specific for 
intestinal GIST, occur in the KIT extracellular domain. Exon 9 mutations are associated with a 
lower response to imatinib and a poorer PFS. These differences translate into significantly longer 
event-free and overall survival among the exon 11–mutant group versus the other two groups. Thus, 
even though wild-type and exon 9–mutant forms of KIT are equally sensitive to imatinib in vitro, 
tumors with these genotypes are less responsive to treatment than are exon 11–mutant tumors. 
[10,42]. Patients with a PDGFRA point mutations (in particular D842V) show a scarce response to 
imatinib therapy. This is consistent with in vitro data showing relative resistance of this variant to 
imatinib [9,44]. 
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2.1.2 Resistance to imatinib 
Non achievement of sTable disease or progression of disease within 6 months of an initial clinical 
response (KIT exon 9 mutation or no detecTable kinase mutation – wild-type tumors, PDGFRA 
exon 18) is termed as primary resistance, occurs in 10%-20% patients and relates to the mutational 
profile of the tumor. Most of wild-type GISTs display primary resistance [45,46]; progression after 
more than 6 months of clinical response is defined as secondary resistance. This has been attributed 
mainly to: 
• genomic amplification (Figure 5),  
• overexpression of KIT/PDGFRA without new point mutations,  
• loss of KIT expression, accompanied by activation of an alternative tyrosine kinase or other 
oncogenes.  
• acquisition of new kinase mutations. 
Although the 2 years survival of patients with metastatic GIST treated with imatinib, approximates 
70% of the patients develop disease progression by 2 year. 
The most common mechanism of secondary resistance appears to be the appearance of the KIT 
kinase domain mutations. Therapeutic options for patients whose GISTs progress on imatinib 
consider dose escalation or treatment with other TKI.  


 
Figure 5. On the left: FISH 
analysis of a GIST patient with KIT 
amplification. Chromosome 4 
centromere probe is shown in 
orange and the KIT probe in green. 
On the right analysis of GIST 
patient without KIT amplification 
(ratio KIT:centromere is 1:1 
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2.2 Sunitinib 
For patients with GIST who develop disease progression during imatinib treatment or are intolerant 
to imatinib, sunitinib is the standard therapy, a second generation TKI. Sunitinib malate 
(SUTENT®, formerly SU11248; Pfizer, New York, USA) is an oral multitarget receptor tyrosine 
kinase inhibitor (KIT, PDGFR ( and ), VEGFR 1,2,3, and FLT3, CSF-1R, and RET that has 
shown anti-angiogenic and antitumor activities in several in vitro and in vivo tumor models. 
Sunitinib has been approved by the FDA on January 26
th
, 2006 for the treatment of patients with 
imatinib refractory or intolerant GIST. Currently, sunitinib is the only second line, FDA approved 
drug treatment for GIST. 
Sunitinib, as well as imatinib, binds to the inactive conformation of the target tyrosine kinases and 
inhibits binding of ATP. Despite this similarity, sunitinib has the potential for activity in imatinib-
resistant GIST, presumably through unique binding characteristics and broader spectrum of kinase 
inhibition, including the tumor-associated angiogenic VEGFR family of tyrosine kinases (Figure 6) 
[48].  


The clinical beneﬁt of sunitinib is genotype-dependent on both the primary and secondary KIT 
mutations. It has been described it gives at least short-term clinical beneﬁts in about 65% of GIST 
patients who are refractory to imatinib. Particularly, it shows superior efﬁcacy in GIST patients 
hosting KIT exon 9 mutations [49]. Unfortunately, only about one-quarter of patients who are 
switched to sunitinib will continue to have responsive disease a year later [48]. 
Sunitinib has been shown to be effective with certain mutations that are resistant to imatinib; 
however, genotype analysis showed that patients with secondary KIT mutation affecting the 
activation-loop domain have PFS and OS. Clinically, some patients with secondary KIT mutation 
involving activation-loop domain experienced rapid disease after switching their treatment from 
Figure 6. Kinase that 
bind imatinib and 
sunitinib are shown in 
red circles; larger circles 
indicate higher affinity 
binding. Interaction with 
Kd<10 are shown. 
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imatinib to sunitinib [50]. Profiling of sunitinib against imatinib-resistant kinases (i.e., KIT with 
primary plus secondary mutations) has shown that sunitinib potently inhibits imatinib-resistant KIT 
ATP/drug-binding pocket mutations, but has little activity against imatinib-resistant KIT activation 
loop mutations [49]. Thus, many imatinib-resistant mutations confer cross-resistance to sunitinib, 
thereby accounting for the relatively short PFS, approximately 6-9 months, with second-line 
sunitinib [51]. 
Despite these considerations, at the moment, sunitinib remains the standard of care for IM-
refractory GISTs regardless the status of their secondary KIT mutation. 
2.3 Regorafenib 
Regorafenib (STIVARGA, formerly BAY 73-4506, BAYER, Levurkusen, Germany) is an orally 
available multikinase inhibitor with activity against multiple targets, including KIT, PDGFR, 
VEGFR1, R2, R3, TIE2, RET, FGFR 1, RAF, and p38 mitogen-activated protein kinase (MAPK) 
[52,53]. On February 25
th
, 2013 the US FDA approved regorafenib to handle patients with 
advanced GIST that cannot be surgically removed and no longer respond to other FDA-approved 
treatments for this disease. Safety and effectiveness of regorafenib were assessed in a clinical study 
involving 199 patients with unresecTable GIST that progressed after treatment with imatinib or 
sunitinib. Patients were randomly assigned to receive either regorafenib or a placebo. All patients 
received optimal supportive care, which includes treatments for the management of side effects and 
symptoms related to the tumor. Patients enrolled in the study took regorafenib or placebo until 
either the cancer progressed or side effects became unaccepTable. Results showed that patients 
treated with regorafenib had a delay in tumor growth (PFS) that was, on average, 3.9 months later 
than patients who were given placebo. Patients who received the placebo were given the 
opportunity to switch to regorafenib when their cancer progressed [52,53]. 
2.4 Emerging treatment for GISTs 
The progress made in the management of GISTs has been possible because researchers around the 
world have worked together to study new drugs. Without clinical trials and the help of those 
patients who take part in them, we would not have the powerful, safe, and effective drugs imatinib 
and sunitinib. Researchers are now studying different compounds as possible new treatments for 
GIST:  
• Nilotinib (Tasigna®, Novartis Pharmaceuticals) is used as first line treatment in leukemia 
patients (CML, Chronic myeloid leukemia), resistant or itolerant to imatinib. Nilotinib acts 
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by blocking the same enzyme activity as imatinib, though in a somewhat different way. 
Although nilotinib has shown some benefit, there is not enough information to suggest that 
nilotinib is more effective than imatinib in GIST. However, nilotinib may be able to control 
GIST in patients resistant to both imatinib and sunitinib.
• Pazopanib (Votrient®, GlaxoSmithKline Pharnaceuticals) is approved for patients with 
kidney cancer. Some early reports suggest that pazopanib might also be useful in GIST. To 
date, phase II trial is completed and a phase III trial is ongoing.
• Sirolimus (Rapamune®, Pfizer Pharmaceutical), everolimus (Afinitor®, Novartis 
Pharmaceuticals), temsirolimus (Torisel®, Wyeth Pharmaceuticals), and ridaforolimus 
(AP23573, Merck and ARIAD Pharmaceuticals). Besides Tyrosin kinase inhibitor drugs, 
there are many other proteins involved in mTOR pathway that could be of interest as 
biological target. Many of these drugs have been tested in combination with either imatinib 
or sunitinib in GIST and other cancers to see whether their combined use is more effective 
than one drug alone. Presently these agents are in phase I or II clinical trials.
• HSP90 inhibitors, (as AT13387, Astex Pharmaceuticals) block a key protein inside 
cancer cells, HSP90. HSP90 is a chaperone for which KIT is a client protein, so it
contributes to GIST growth. AT13387 combined with imatinib is currently being studied in 
phase II clinical trials.
• PI3K inhibitors, (as BYL719, Novartis Pharmaceuticals) is the first oral PI3K inhibitor 
that strongly and selectively inhibits the PI3K alpha isoform of PI3K. Its biological activity 
correlates with inhibition of various downstream signaling components of the PI3K/Akt 
pathway and it inhibits the proliferation of breast cancer cell lines harboring PIK3CA 
mutations. A phase I clinical trial is ongoing. 
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Specific background 
Cancer treatment is complicated by the myriad of treatment options and the lack of patient-specific 
information that may help clinicians select the best option therapy. There are two genomes relevant 
in cancer handling: the patient (germline) and the tumor (somatic). Together, these two genomes 
bring to treatment outcome through four processes: the germline genome modulates treatment 
exposure and toxicity while the somatic genome primarily determines tumor prognosis and response 
[54]. 
3. Germline genome: 
pharmacogenetics and pharmacogenomics 
In a large patient population, a drug that is proven effective in many patients often fails to work in 
many others. Moreover, when it works, it could cause important serious side effects, even death, in 
a limited number of patients [55]. It is well documented that the large variability in efficacy and 
adverse reactions (ADR) occurring among different patients is the major determinant of use and 
limitation of drug in the clinical setting. Factors that can cause inter-variation among different 
patients treated with the same drug are various and complex, and include age, sex, lifestyle, 
environmental factors and especially genetic factors [56]. 
Pharmacogenetics focuses on the variants within one or more candidate genes while 
pharmacogenomics evaluates the entire genome for associations with pharmacological phenotypes 
[57]. This discipline has its origin in 1950s with the growth of human biochemical genetics. The 
role of genetics as a potential cause of ADR has been review for the first time by Motulsky in 1957 
in “Drug reaction, Enzymes and biochemical Genetics”. The term pharmacogenetics was created by 
Friedrich Vogel in 1959. In the late 1960s Vessel showed similarity of drugs disposal in identical 
twins, who shared 100% of their genes, unlike fraternal twins with only the 50% in common.  
In the last decades, pharmacogenetic research has been hit by an explosion of interest by physician, 
geneticist and the pharmaceutical industry, as reflected by the rapid increase in the number of 
papers in the medical literature [58]. The rapid accumulation of knowledge of genome desease and 
genome-drug interaction has also driven the transformation of pharmacogenetics into a new entity 
of human genetics – pharmacogenomics – and provided the rationale for the hope of an 
individualized medicine [57]. 
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The term pharmacogenomics was introduced in 1990s as a result of the knowledge gained from of 
the Human Genome project, and the development of genome sciences [58,59]. 
The main aim of pharmacogenetics and pharmacogenomics is to individualize medicine according 
to the specific genetic make-up of a given patient. Environment, diet, age, lifestyle and state of 
health can all influence the individual response to any pharmacological treatment, but 
understanding the influence of genetics could be the key to develop personalized medicine 
characterized by greater efficacy and safety. [59].
3.1. Single Nucleotide polymorphisms (SNPs) 
Polymorphisms are genetic variations that occur with different frequency in different populations. 
These variations could be represented by insertion or deletions, but the most common variations are 
SNPs. A SNP is a DNA sequence variation, with a frequence > 1%, occurring when a single 
nucleotide in the genome differs among members of species within an individual. In the human 
genome the number of SNPs is around 3.2 milions and they are responsible for the 90% of human 
genetic variability [60]. SNPs are classified in three groups depending on where they are located in 
the genome: (i) c-SNP, variations located in coding region, exons, whose presence could modify or 
not the aminoacid sequence of the protein (non sinonimus and sinonimus, respectively) (ii) p-SNP, 
located in perigenic region, and (iii) r-SNP, random SNPs located in the intragenic regions, do not 
influence transcript or protein, but they can modify the DNA third structure, interfering with 
chromatin or DNA replication (Figure 7). 

Figure 7. SNPs classification depending on their position. 
 
Specific background 

14
Polymorphisms in key genes encoding drug transporters and metabolizing enzymes influence 
intracellular drug delivery. Pharmacogenetics has indeed demonstrated to be a potential source of 
biomarkers able to predict drug response and adverse drug reactions. 
The rapid development of techniques in the area of genome analysis has eased the identification of 
new pharmacogenomics biomarkers. Such biomarkers mainly originated from genes encoding drug-
metabolizing enzymes, drug transporters and drug targets. Some of these are now integrated by the 
US FDA and the European Medicines Agency (EMA) into drug label inserts [61]. In Table 1 are 
reported some significant examples of pharmacogenomics biomarkers in the context of cancer, 
describing prevalence, authority guidelines and relative importance [61]. 
Table 1. Pharmacogenenomic biomarkers in the context of desease, prevalence, authority guidelines and relative 
importance. 

a The frequency varies across different populations. Carrier refers to the frequency of subjects with at least one  allele variant.  
b The number of asterisks denotes the authors opinion of the raltive importance with ***denoting the highest significance. 
PC Promising candidate. 
Various initiatives have been suggested such as a pharmacogenetic research network that includes a 
series of integrate groups with expertise in pharmacology, genomic science, bioinformatics and 
clinical science. The group located at Standford University is responsible for the development of a 
public database that focuses on genotype data relevant to pharmacogenomics. This is only an 
example of what it is going on this panorama, although clinical translation remains the first 
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necessary step. Pharmacogenomics studies require a large number of subjects and multi-disciplinary 
teams with complementary expertise, as well as the ability to genotype a very large number of 
polymorphism and haplotypes [62]. 
The main current problems related to pharmacogenomics are: poorly defined phenotypes; 
significance of non-functional mutations; ethical aspects such as the use of genomic information; 
unclear sources for covering diagnostic costs and lack of founding for large prospective randomized 
studies, besides retrospective studies. Currently the most important aspect is a careful cost-benefit 
analysis of genetic testing closely followed by the specific need of educating the industrial and 
chemical research to the use of genetic testing [61]. 
Pharmacoepigenetics offers another level of explanation for inter-individual variations in drug 
response that cannot be clarified on the basis of genetic polymorphism. Many genes encoding 
enzymes, drug transporters, transcription factors, drug targets and nuclear receptors are under 
epigenetic control. Epigenetics includes covalent modifications of DNA and histones, DNA packing 
around nucleosomes, chromatin folding and attachment to the nuclear matrix and regulatory non 
coding RNAs, like small interfering RNAs (siRNAs) and microRNA (miRNAs). This emerging 
area is far to be fully elucidated, and represents an attractive field of investigation connecting 
environment and the genome [63,64]. 
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4. Somatic genome: 
tumor prognosis and response
A healthy cell becomes cancerous by losing its ability to suitably regulate its replication. This initial 
genetic aberration can be a simple change in DNA sequence or a change that impacts an entire gene 
or chromosomal region. This malignant cell represents the seed from which a tumor arise, and the 
genome of this cell is the founder somatic genome. Through repeated cellular replication this 
somatic genome acquires additional abnormalities. Some of these acquired variants will further 
drive cancer progression, such as mutations in genes that 
are responsible for maintaining DNA replication accuracy 
or controlling metastatic spread. The initial and acquired 
aberrations determine the behavior of the primary tumor, in 
particular its ability to metastasize, and the treatment 
mechanisms that it will be sensitive to. Thus, prediction of 
tumor prognosis and response can be affectuated by 
understanding the somatic genetics [55]. 
About 90% GISTs are characterized by one primary 
somatic mutation, mainly in exon 9 or 11 (Figure 8). This 
gain of function mutation determines a constitutive, ligand 
indipendent activation (Figure 9). The responsiveness of GIST to imatinib varies by primary KIT 
genotypes, which is now 
considered the most 
important factor in predicting 
outcome. In particular, 
patients with exon 11 
mutations, despite a poor 
clinical prognosis prior to the 
imatinib era, are much less 
likely to experience treatment 
failure than patients with 
exon 9 mutations or without 
detectable mutation in KIT 
and PDGFRA [65]. 
Figure 8. KIT exon sequence: tumor samples 
with normal DNA (upper panel) and with a 
W557R primary mutation (lower panel). 
Figure 9. Two kit receptors normally dimerize in the presence of the phisiological ligand 
SCF to initiate downstream signaling (left). Mutations in the receptor cause abnormal 
constitutive signaling without  SCF stimulation (right).
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Mutational analysis of KIT and PDGFRA in GISTs has important implications in diagnosis and 
therapy decision and prediction of response to imatinib treatment. 
Approximately 10% of GIST patients show primary resistance and the vast majority eventually 
develop secondary resistance and disease progression. Considering the heterogeneity in the 
mutational spectrum of GIST patients, it is interesting to thoroughly compare the treatment 
response, according to the mutational types, in the imatinib era. To date, according to the literatures  
the responsiveness of GIST to imatinib varies by primary KIT genotype [9, 66-68]. A mistake in 
KIT and PDGFRA mutation analysis might have dramatic consequence for patients: some will be 
treated with the wrong dose of imatinib (KIT exon 9 false negative), others without benefit 
(PDGFRA exon 18 D842V false negative) Considering these studies, on average approximately 
71% of GIST exon 11 mutants reached an objective response (complete and/or partial response) 
compared with approximately 36% of exon 9 and 41% of WT-GISTs. Similarly, approximately 
26% of wt-GISTs and approximately 16% of patients with exon 9 mutation experienced progressive 
disease, compared with only 5% of GISTs with exon 11 mutations. These findings are indeed 
corroborated by thefact that exon 11 mutant patients have a significantly better PFSand OS than 
patients with a tumor with exon 9 mutation or no detecTable KIT or PDGFRA mutations [65]. 
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5. Imatinib transporter genes 
It is well recognized that inter-patient variability in drug response reflects the systemic levels or 
intracellular concentrations of the drug, known to be associated with its pharmacokinetics 
(absorption, distribution, and metabolism) of the drug itself. Imatinib is metabolized by the 
cytochrome-P450 - mostly CYP3A4 and 3A5 isoforms. The active uptake of imatinib into cells is 
known to be mediated mainly by the hOCT1 transporter (encoded by the SLC22A1 gene), whereas 
its efflux is mediated by the ABC transporters, in particular ABCB1 (also known as MDR1) and, to 
a lesser extent, ABCG2 (Figure 10) [69-73]. Besides these, other transporters may be important in 
the absorption, distribution, and elimination of imatinib, including the families of organic cation 
transporters (OCT) and organic 
anion transporters (OAT). In 
particular, a recent study by Hu et 
al. identified imatinib as a substrate 
of OATP1A2 (encoded by 
SLCO1A2), [72] whereas the 
involvement of members of the 
OCTN family as imatinib 
transporters is still uncertain. 
Inter-patient variability in imatinib 
metabolism/transport is substantial 
and thus far unexplained. A 
possibility is that genetic 
polymorphisms in genes encoding 
imatinib-metabolizing enzymes and 
transporters may influence the 
imatinib uptake into target cells. Consequently, genetic polymorphisms on the candidate genes 
CYP3A4/3A5, MDR1, ABCG2, OATP1A2, OCTN1 (encoded bySLC22A4), OCTN2 (encoded 
bySLC22A5) and hOCT1 could affect expression of the corresponding proteins and thus may 
predict differences in responses to imatinib. 

Figure 10. Main players in imatinib transport.
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6. Folate metabolism pathway 
Folate metabolism supports numerous critical intracellular reactions, including DNA synthesis, 
repair, and methylation (Figure 11). DNA methylation status is essential for healthy development 
and maintenance of cellular homeostasis and functions in adult organisms, including silencing of 
repetitive DNA elements and proper expression of genetic information [74]. The accurate 
maintenance of DNA synthesis, repair, and methylation patterns is fundamental, and its balance in 
mature cells is maintained by the concerted action of more than thirty enzymes [75]. Figure 10 
represents a simplified diagram of the key enzymes that take part in the folate metabolic pathways. 
They include methylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS), 
methionine synthase (MTR), methionine synthase reductase (MTRR), serine 
hydroxymethyltransferase (SHMT), dihydrofolate reductase (DHFR), reduced folate carrier (RFC), 
and folate receptor 1 (FOLR). These enzymes are highly polymorphic, and several functional 
genetic polymorphisms have been attracting research interest. In particular, several of these 
polymorphisms have been associated with decreased or increased enzymatic activities, with 
possible alteration in DNA synthesis, repair, and methylation processes. Aberrant methylation 
patterns, have been associated with various diseases including cancer and neurodegenerative 
disease. Additionally, polymorphisms in genes involved in the folate metabolisms have been 
associated with cancer risk, including colorectal and gastric cancer, vascular disease, depression and 
Down’s syndrome. Currently, there are evidences of an association between DNA methylation level 
and polymorphisms in 
folate metabolism genes. 
The alteration of one or all 
of these processes could 
explain the association that 
have been found between 
some of these 
polymorphisms and risk of 
various malignancies, 
including breast, colorectal, 
and prostate cancer, and 
acute lymphoblastic 
leukemia [76]. 
Figure 11. Key enzymes in the folate metabolic pathways. Image edited from Nat Rev 
Cancer. 2003 Dec;3(12):912-20. Cancer pharmacogenetics: polymorphisms, pathways and 
beyond. Ulrich CM, Robien K, McLeod HL. 
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Imatinib was the first inhibitor of c-KIT tirosin kinase to be licensed by health authorities and 
currently represents the first line treatment for GIST [37-39]. Despite the enormous success, 
resistance against imatinib emerges in a significant proportion of patients. In most GISTs initially 
responding to imatinib, development of resistance over time is common, and the occurrence of 
secondary resistance represents the main cause of disease progression. Different mechanisms 
leading to imatinib resistance have been identified and extensively investigated, and the most 
common is related to the alteration of the receptor signaling, in particular the acquisition of 
secondary mutations [69]. In addition, up-regulation of liver drug metabolizing enzymes [69], 
causing increased clearance of imatinib and up-regulation of drug transporters may be potential 
mechanisms [71].  
An attractive alternative is represented by inter-individual differences in imatinib pharmacokinetics. 
In this process, the genes that control drug absorption, distribution, metabolism and excretion play a 
key role. Indeed, all of the drug metabolizers and transporters contain many genetic polymorphism, 
which might cause large inter-individual variability in imatinib plasma concentration and 
disposition. 
For the reason mentioned above, the general aim of my three-years research period was to 
investigate the relationship between biomarkers and drug response – and resistance of course – on 
the basis of both an in vivo and in vitro approach. 
Following the hypothesis that polymorphisms in genes encoding for imatinib transporters and 
metabolism enzymes may influence imatinib concentration delivered to target cells [70-73], the 
first objective was to conduct a retrospective study in a subset of 60 patients enrolled in a 
multicentric randomized phase III study, and to investigate a panel of SNPs in genes involved in 
imatinib transporters (I) and in the folate metabolism pathway (II) [74-76]. 
Based on the recognition that clinical progression of GIST during TKI therapy is often multifocal, 
TKI resistance mutations have been assessed in only single, or few, progressing metastases per 
patient and the heterogeneity of these mutations, in a given patient, remains unclear [77,78], the 
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second objective was to characterize in-depth the heterogeneity of KIT mutations and the drug-
resistance mechanisms using a sensitive next generation sequencing approach. 
 
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First objective 
The first objective is made up by two parts: 
I. Association between imatinib transporters genotype and response in 
GIST patients receiving imatinib therapy.  
II. Folate-related polymorphisms in GIST: susceptibility and correlation 
with tumor characteristic and clinical outcome.  
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I.  Association between imatinib transporters genotype and 
response in GIST patients receiving imatinib therapy 
  
Materials and methods 
 Study population – A total of 54 unresecTable/metastatic GIST patients receiving standard first-
line imatinib 400 mg daily were retrospectively enrolled in this pharmacogenetic study. Twenty-
nine patients were enrolled at Sant’Orsola-Malpighi Hospital, Bologna, and 25 at Istituto Nazionale 
dei Tumori, Milan, Italy. A written informed consent was required and the study was approved by 
the Ethics Committees of the two institutions. Patients with available peripheral blood were eligible. 
Patients characteristics and clinical features of their tumors are summarized in Table 2.
Evaluation of imatinib response - Time to progression (TTP) was calculated from the start of 
imatinib therapy to the date of disease progression documented by the CT scan performed 
approximately every 3-4 months. In one case, the disease re-evaluation by CT scan was done earlier 
due to clinical progression. 
Genotyping analysis - DNA was isolated from fresh or frozen whole blood using a DNA isolation 
kit from QIagen (QIAamp
®
 DNA Mini Kit, Qiagen, Hilden, Germany). Characteristics of the 
studied polymorphisms - three insertion/deletion and 28 single nucleotide polymorphisms, from 
now on all referred as SNPs in the text - are reported in Table 3a. Genotypes were determined by 
polymerase chain reaction (PCR) - based assays [restriction fragment length polymorphism (RFLP) 
and/or real-time] according to published methods [79] or by Taqman
® 
assay PCR. Positive and 
negative controls were included in each reaction as quality control. In addition, accuracy of 
genotyping was confirmed by repetition of 100% of the samples.  
Table 2. Patient and disease characteristics of 
the study population (n = 54). 
Gender, n (%) 
    Female 19 (35.2) 
    Male 35 (64.8) 
Age at diagnosis, years 
    median (range) 58 (18-83) 
a
 None of the analysed subjects had tumour size < 2 
cm; 
b
 50 x High power filed. 
Tumour site, n (%) 
    Stomach 30 (55.6) 
    Small Intestine 21 (38.9) 
    Other 3 (5.5) 
Tumour size a, n (%) 
    2 - 5 cm 5 (9.2) 
    5 - 10 cm 17 (31.5) 
     10 cm 19 (35.2) 
    missing 13 (24.1) 
Mitotic index b, n (%)  
    < 5  11 (20.4) 
    6-10 4 (7.4) 
     10 15 (27.8) 
    missing 24 (44.4) 
Mutational status, n (%) 
    KIT exon 11 31 (57.4) 
    Other than PDGFR D842V  
and PDGFR/KIT WT 
4 (7.4) 
   missing 19 (35.2) 
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PCR RFLP – the main components to perform a PCR are primers, nucleotide sequences 
complementary to the target region, DNA polymerase, necessary to enzymatically assemble a new 
strand of DNA, deoxynucleotide triphosphates (dNTPs), the building blocks from which the DNA 
polymerase synthesize a new DNA strand, buffer solution and usually divalent cations that help the 
reaction (i.e. MgCl2) 10ng DNA was added at this mixture and the thermal cycling program were 
performed (Table 3). The DNA is replicated in every cycle and the amount increased exponentially. 
The amplification of the sequence of interest is followed by the incubation with an appropriate 
restriction enzyme that recognize, if present, the restriction site, creating DNA fragments. The 
fragments obtained were separated through electrophoresis at 200 V for 30 minutes, on pre-cast 
polyacrylamide gels 10% TBE (Bio-rad, Hercules, CA, USA). The DNA was then analyzed using 
Ethidium Bromide, an intercalating agent commonly used as a fluorescent tag. When exposed to 
UV ray its fluorescence is 20-fold higher after binding DNA. The image of the gel was acquired 
using a digital photo camera connected to VERADOC-4000 (Bio-rad) and visualized with 
QUANTITY ONE software. Three were the possible situations that can emerge from the analysis: 
homozygosis for the wild-type (wt) allele, homozygosis for the SNP or heterozygosis, in which one 
allele is wt and the other one is SNP. 
Real Time PCR – Real-time PCR (RT-PCR or qRT-PCR) is a variation of the standard PCR 
technique used to quantify DNA o mRNA in a sample. Using sequence specific primers, the relative 
numbers of copies of a particular DNA or RNA sequence can be determined. Quantification of 
amplified product is obtained using fluorescent probes and specialized machines that measure 
fluorescence while performing temperature changes needed for the PCR cycles (Figure 12). More 
specifically for our use, an allelic discrimination assay was used to detect variants of a single 
nucleic acid sequence. One fluorescent dye detector is a perfect match to the wt (allele 1) and the 
other one is a perfect match with the SNP allele (allele 2). The allelic discrimination assay classifies 
unknow samples as i) homozygotes (samples having only allele 1 or 2) and ii) heterozygotes 
(samples having both allele 1 and 2). In particular, the allelic discrimination assay measures the 
change in fluorescence of the dyes associated with the Taqman probes VIC
®
 and FAM
®
 (Applied 
Biosystems, Foster City, CA), that selectively bind wt or SNP allele (Figure 12). The reaction was 
prepared using 10ng DNA, Taqman genotyping assay(20X or 40X), Taqman Universal Master Mix 
(2X) and water RNAse free, for a total volume of 25ul. The analysis was performed using 7900 HT 
Fast Real Time PCR system (Applied Biosystem).  
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Figure 12. Each TaqMan® MGB probe anneals specifically to its complementary sequence between the 
forward and reverse primer sites. When the oligonucleotide probe is intact, the proximity of the quencher 
dye to the reporter dye quenches the reporter signal. AmpliTaq Gold® DNA polymerase extends the 
primers bound to the genomic DNA template. AmpliTaq Gold® DNA polymerase (with its 5´ nuclease 
activity) cleaves probes that are hybridized to the target sequence. Cleavage of the probes hybridized to 
the target sequence separates the quencher dye from the reporter dye, resulting in increased fluorescence 
by the reporter. The fluorescence generated by PCR amplification indicates which alleles are present in 
the sample. 
Table 3. SNPs description. 
[A] RT = Real-Time PCR with TaqMan allelic discrimination assay [Applera, Foster City, USA]; 
    RFLP = PCR-RFLP and M = Multiplex PCR, analysis carried out according to published methods [reference 
parenthetically] or as standardized in our laboratory (primer set, T (°C) of annealing and restriction enzymes (Fermentas, 
Vilnius Lithuania) described].
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Table 3. SNPs description. 
Gene [full name; Protein name]   SNP ID METHOD [A]  
SLC22A1 [Solute carrier family 22 (organic cation transporter - OCT1) family 22, member 1] 
rs12208357 [R61C] RT TaqMan assay C_30634096_10 
rs683369 [L160P] RT TaqMan assay C_928536_30 
rs4646277 [P283L] RT TaqMan assay C_30634088_10 
rs4646278 [R287G] RFLP  f_GCGATGGCTCCCTTTTG 
r_TTAGACCCCGACCCAAGACCAC 
rs2282143 [P341L] RT TaqMan assay C_15877554_40 
rs72552763 [MI420I] RT TaqMan assay C_34211613_10 
SLC22A4 [solute carrier family 22 (organic cation transporter - OCTN1), member 4] 
rs1050152 [L503F] RT TaqMan assay C_3170459_30 
SLC22A5 [Solute carrier family 22 (organic cation transporter - OCTN2), member 5] 
rs2631367 [5’ UTR] RFLP [Török et al., 2005] 79
rs2631370 [5’- near gene] RT TaqMan assay C_2843383_10 
rs2631372 [5’- near gene] RT TaqMan assay C_26479165_10 
SLCO1A2 [Solute carrier organic anion transporter family (OATP) member 1A2] 
rs11568563 [E172D] RT TaqMan assay C_25605897_10 
SLCO1B3 [Solute carrier carrier organic anion transporter family (OATP) member 1B3] 
rs4149157 [5’ UTR] RFLP [Tsujimoto et al., 2008] 80
rs4149158 [5’ UTR] RFLP [Tsujimoto et al., 2008] 80
rs4149117 [S112A] RT TaqMan assay C_25639181_40 
rs7311358 [M233I] RT TaqMan assay C_25765587_40 
ABCA3 [ATP-binding cassette sub-family A, (ABC1) member 3]
rs323040 [Intronic] RT TaqMan assay C_11292220_10
rs4146825 [5’ UTR] RT TaqMan assay C_32374235_10 
ABCB1 [ATP-binding cassette sub-family B, (MDR/TAP) member 1; P-gp (P-glycoprotein)] 
rs10245483 [Promoter region] RT TaqMan assay C_2573447_20
rs3213619 [Promoter region] RT TaqMan assay C_27487486_10
rs1128501 [G185V] RT TaqMan assay C_7586664_10 
rs1128503 [G412G also C1236T] RT TaqMan assay C_7586662_10 
RFLP [Goreva et al., 2004]81
rs60023214 [I1145I also C3435T] RFLP [Jamroziak et al., 2004] 82
rs2032582 [A893S/T also G2677T/A] M [Kurzawski et al., 2006] 83
ABCC4 [ATP-binding cassette sub-family C, (CFTR/MRP) member 4] 
rs3765534 [E757K] RT TaqMan assay C_27478235_20
rs9561765 [Intronic] RT TaqMan assay C_31356298_10 
ABCG2 [ATP-binding cassette sub-family G, (WHITE) member 2] 
rs2231137 [M12V] RFLP [Hu et al, 2007] 84
rs2231142 [Q141K] RT TaqMan assay C_15854163_70 
CYP3A4 [cytochrome P450, family3, subfamily A, polypeptide 4; CYP3] 
rs2740574 [5’ Near Gene] RFLP [Radriguez-Antona et al., 2005] 85
rs28371759 [L293P] RT TaqMan assay C_27859823_20 
CYP3A5 [cytochrome P450, family3, subfamily A, polypeptide 5; CYP3] 
rs776746 [Splicing site] RFLP [Hu et al., 2005] 86
rs28365083 [T398N] RFLP [van Schaik et al., 2002] 87
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Statistical analysis - The distribution of genotypes was tested for Hardy-Weinberg (HW) 
equilibrium using the online HW test tool offered by the Institute for Human Genetics, Technical 
University Munich (http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl). Survival analysis 
methods were used to examine the relationship between genotypes [homozygous wild-type, 
heterozygous and homozygous for the variant allele (SNP)] and GIST time to progression. In 
univariate analysis, the survival curves were estimated and plotted with the Kaplan-Meier method. 
The curves were compared with log-rank test of equality of survivor functions (statistical 
significance defined as p < 0.05). In multivariate analysis, hazard ratios (HR) and 95% confidence 
interval (95% CI) were estimated with Cox proportional hazards models, using gender, age, tumour 
site and size, mutational status and status at diagnosis, as covariates in addition to the genotype. The 
proportional hazards assumption was tested (p > 0.05) using Schoenfeld residuals. Multiple logistic 
regression was used to assess the relation between individual SNPs and primary resistance. 
Statistical analysis was conducted using Stata Intercooled version 11.0. 
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Results 
Characteristics of the study population - The cohort of 54 Caucasian GIST patients was made up of 
65% men and 35% women (median age at diagnosis 58 years). The most common primary sites 
were the stomach (55.6%) and the small intestine (38.9%). Nearly three-quarters of patients had 
metastatic disease, with liver and peritoneum as the most common sites of metastases. Thirty-one 
patients (57.4%) harboured KIT exon 11 mutations, while only one patient had a KIT exon 9 
mutation. Three patients (5.6%) had a PDGFR mutation, excluding the D842V, since GISTs 
harbouring this mutation, as well the PDGFR/KIT WT GISTs, were not included in the study 
being assumed to be resistant to imatinib. In nineteen GISTs, mutational status was unknown, due 
to insufficient or unavailable biological material for the analysis. 
Genotype distribution. Genotype distribution of the 31 candidate SNPs are summarised in Table 4.  
 Table 4. Genotype frequency of the 31 candidate SNPs. 
Gene
     SNP ID
Major/Minor  
allele 
MAF HWE        P value
SLC22A1 – OCT1 
rs12208357 C/T 0.09 0.37 
rs683369 C/G 0.17 0.62 
rs4646277 C/T 0.00 --- 
rs4646278 C/G 0.00 --- 
rs2282143 C/T 0.00 --- 
rs72552763 GAT/- 0.18 0.34 
SLC22A4 – OCTN1
rs1050152 C/T 0.43 0.78 
SLC22A5 – OCTN2
rs2631367 C/G 0.51 1.00 
rs2631370 A/G 0.32 0.37 
rs2631372 C/G 0.40 0.25 
SLCO1A2 – OATP1A2 
rs11568563 A/C 0.04 1.00 
SLCO1B3
rs4149157 
ATATTCACTTGGT
ATCTG/- 
0.31 0.75 
rs4149158 TTTA/- 0.31 0.75 
rs4149117 G/T 0.10 1.00 
rs7311358 A/G 0.10 1.00 
ABCA3  
rs323040 G/A 0.17 1.00 
rs4146825 C/T 0.00 --- 
ABCB1
rs10245483 G/T 0.48 0.79 
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rs3213619 A/G 0.00 --- 
rs1128501 C/A 0.00 --- 
rs1128503 C/T 0.47 0.01 
rs60023214 C/T 0.54 0.58 
rs2032582 G/T or A 0.46 0.10 
ABCC4
rs3765534 C/T 0.00 --- 
rs9561765 G/A 0.06 1.00 
ABCG2
rs2231137 G/A 0.08 1.00 
rs2231142 G/T 0.08 0.30 
CYP3A4
rs2740574 A/G 0.02 1.00 
rs28371759 A/G 0.00 --- 
CYP3A5
rs776746 G/A 0.04 1.00 
rs28365083 C/A 0.00 --- 
Nine SNPs (SLC22A1 rs4646277, rs4646278, rs2282143, ABCA3 rs4146825, ABCB1 rs3213619, 
rs1128501, ABCC4 rs3765534, CYP3A4 rs28371759, and CYP3A5 rs28365083) were homozygous 
for the major allele in all patients and were excluded from further analyses. As expected from the 
literature, in the SLCO1B3 gene we found the rs4149157 in complete linkage disequilibrium with 
the rs4149158, and the rs4149117 completely consistent with the rs7311358. Deviation from the 
HW equilibrium was observed for a single SNP (ABCB1 rs1128503); departure from HW 
equilibrium was not observed for any other SNPs. The distribution of genotypes was similar to 
those previously reported by us in CML Caucasian patients [79] or in the publicly available 
database NCBI (dbSNP) for Caucasians. 
Treatment outcome of imatinib therapy and genotypes. With a median duration of imatinib 
administration of 36,9 months, the best results during therapy were partial response and sTable 
disease in 90.7% of patients. With a median follow-up of 36.9 months, progressiove disease was 
observed in 26 cases (48.1%), with a median TTP of 21.8 months (range 1.6-58.2). 
Presence of the C allele in SLC22A4 (OCTN1 rs1050152) had a significantly favourable impact on 
TTP [HR 2.94, 95% CI 1.20-7.17, P = 0.018; (Table 5)]. The two minor alleles (G) in SLC22A5
(OCTN2 rs2631367 and rs2631372) were also significantly associated with a prolonged TTP (P = 
0.049 and P = 0.050 respectively; Table 5). None of the other analysed SNPs correlated with the 
TTP. 
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Alleles were correlated with TTP based on the Kaplan-Meier method. Presence of the minor allele 
in SLC22A4 (TT rs1050152), was associated with reduced TTP (P = 0.013; Figure 13). 
Similarly, presence of the SLC22A5 CC (rs2631367) and CC (rs2631372) genotype was associated 
with reduced TTP in both cases (P = 0.042 and P = 0.045 respectively; Figure 14).  
Table 5. Most relevant association between TTP and candidate genotypes. 
Gene
SNP ID
Referent/adverse 
Genotype Hazard ratio [95% CI] P value
 SLC22A4 – OCTN1
rs1050152 CC or CT/TT 2.94 [1.20-7.17] 0.018 
 SLC22A5 – OCTN2
rs2631367 CG or GG/CC 0.43 [0.18-1.00] 0.049 
rs2631372 CG or GG/CC 0.46 [0.21-1.00] 0.050 
Figure 13. . Kaplan–Meier TTP estimates for SLC22A4 (OCTN1) genotypes – rs1050152.
A 
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Figure 14. A. Kaplan–Meier TTP estimates for SLC22A5 (OCTN2) genotypes – rs1050152. B. Kaplan–Meier 
TTP estimates for SLC22A5 (OCTN2) genotypes – rs261372.
In addition ABCC4 – GA genotype (rs9561765) showed a trend for a possible association with 
prolonged TTP (P = 0.084). Considering the low statistical power because of the sample size, and 
the low frequency (q = 0.06), this SNP may be worthy of further consideration. Based on the 
findings of the present study we stratified the population according to the number of favourable 
genotypes. In particular, we assigned a score of 3 in the presence of all three favourable genotypes –
SLC22A4 – CC+CT (rs1050152), SLC22A5 – CG+GG (rs2631367) and CG+GG (rs2631372) – and 
a score of 0 to 2 according to the presence of zero to two favourable genotypes. A score of three 
was significantly associated with improved TTP (P = 0.040; Figure 15). 

Figure 15. Kaplan–Meier TTP estimates for SLC22A4 (rs1050152) and SLC22A5 rs2631367 and 
rs2631372) genotypes combination. The numbers of 0–3 indicate the number of favourable genotype 
associates with improved TTP. (— 0 to 2 favourable genotypes; ---- 3 favourable genotypes). 
B 
3 
0-2 
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 Cox proportional hazards models examining the association between genotypes and TTP, were 
adjusted for known prognostic factors, including age, sex, site of localization, tumour size, and 
mutational status (Table 6). As expected, size 10 cm was always significantly associated with a 
reduced TTP (P  0.05). In these models SLC22A4 (rs1050152) and SLC22A5 (rs2631367 and 
rs2631372) genotypes, as well as the combination of favourable - SLC22A4 (rs1050152) and 
SLC22A5 (rs2631367 and rs2631372) - genotypes maintained independent predictive value (Table 
6). In addition to these, the ABCC4 AA genotype (rs9561765) was also associated with reduced 
TTP (P = 0.032; Table 6). 
Logistic analyses were performed for association with primary resistance to imatinib. However, the 
primary resistance rate was very low (only 5 patients, the 9.3%, had a primary resistance), and no 
correlation could be detected. 
Table 6. Multivariate Cox regression models for TTP. 
SNP HR (95% CI) P value* SNP HR (95% CI) 
P value*
SLC22A4 - rs1050152 SLC22A5 rs2631367 
  
 TT vs TC+CC 
5.74 (2.01-16.40) 0.001   CG + GG vs CC 0.15 (0.05-0.44) < 0.001 
Tumour size   Tumour size   
  10 cm vs < 10 cm 3.01 (1.13-8.06) 0.028   10 cm vs < 10 cm 3.11 (1.20-8.11) 0.020 
    
SLC22A5 rs2631372 ABCC4 rs9561765 
   
CG + GG vs CC 
0.46 (0.22-0.97) 0.043 GA vs  AA 0.12 (0.02-0.83) 0.032 
Tumour size   Tumour size   
  10 cm vs < 10 cm 2.87 (1.07-7.70) 0.036   10 cm vs < 10 cm 2.71 (0.96-7.64) 0.060 
     
SLC22_A4-A5 Haplotype**   
   
3 vs 1+0 
0.15 (0.05-0.44) < 0.001    
Tumour size     
  10 cm vs < 10 cm 3.11 (0.02-0.44) 0.002    
* Gender, age, and mutational status adjusted. 
** A score of 3 corresponds to the presence of the three favourable genotypes – SLC22A4 – CC+CT (rs1050152), SLC22A5 – 
CG+GG (rs2631367) and CG+GG (rs2631372) – and a score of 0 to 2 to the presence of zero to two favourable genotypes. 
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Discussion 
To the best of our knowledge, this is the first pharmacogenetic study in GIST patients undergoing 
imatinib therapy. Since the introduction of imatinib as standard treatment in GIST patients with 
metastatic and/or unresecTable disease, significant efforts have been made to elucidate the 
mechanisms that could affect its efficacy. As is well known, KIT and PDGFR mutational status 
has a significant impact on response to imatinib treatment. In particular Heinrich et al. reported that 
83.5% of patients with exon 11 KIT mutations achieved an objective response after imatinib 
therapy, compared to 48% of patients with exon 9 mutations [9]. Patients harbouring the PDGFR
exon 18 - D842V - mutation are usually non responsive to imatinib [8,64]. Finally, KIT and 
PDGFR GISTs are also poorly responsive to imatinib, though the percentage of patients achieving 
an objective response or sTable disease is variable, according to different studies [8,9,64]. 
Conversely, patients with KIT exon 9 mutations show better outcomes in response to higher dose of 
imatinib (600/800 mg daily vs 400 mg day) as well as to sunitinib [49]. Certainly, KIT and 
PDGFR mutational analysis represents a good predictive marker of responsiveness to tyrosine 
kinase inhibitors. However, GISTs characterized by the same mutational spectrum often show 
different responses in the clinical practice. In addition, the inability to find secondary mutations in 
some progressive GISTs has suggested the possibility that, besides KIT and PDGFR secondary 
mutations, additional mechanisms may be involved in imatinib resistance [88]. The theory that the 
mutational status cannot explain all the cases of primary/secondary resistance observed, is 
corroborated by the finding that GISTs with secondary KIT activation-loop mutations, expected to 
be insensitive to both imatinib and sunitinib, may still be susceptible to sunitinib [49]. It thus 
appears indispensable to better elucidate the different mechanisms of resistance, which will help to 
define subpopulation of GIST patients who will truly benefit from second-generation tyrosine 
kinase inhibitors, or maybe from imatinib dose escalation or discontinuation. 
Retrospective data  suggested that imatinib plasma levels are associated with progression-free 
survival in advanced GISTs [90-93]. On the contrary, finding have been reported in a recently 
published prospective pharmacokinetic study, the first in GIST patients [94]. The putative role of 
pharmacokinetic in imatinib resistance is still largely unexplored, and today imatinib plasma level 
assessment do not represent a standard procedure in the clinic. However, we cannot exclude that 
imatinib pharmacokinetic properties may impact efficacy of treatment, e.g. time to progression. In 
this perspective, considering the possible influence of polymorphisms in key genes encoding drug 
transporters and metabolizing enzymes on intracellular drug delivery, pharmacogenetics might 
represent a potential source of biomarkers of imatinib effectiveness as highlighted in 
pharmacogenetic studies in CML [79]. However, to our knowledge, the identification of different 
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polymorphisms in imatinib transporters and metabolizing genes has led to the conduction of several 
pharmacogenetic studies in CML patients but not in GISTs [79,95]. 
In this retrospective study, using a multiple candidate gene approach, we found that polymorphisms 
in imatinib transporters genes are associated with TTP. In particular we found that the SLC22A4
variant allele (rs1050152) was significantly associated with a reduced TTP. To us, this finding is 
intriguing, as we found the same polymorphism correlating with the major molecular response rate 
in our set of CML patients [79]. None of the other pharmacogenetic studies has investigated this 
gene, as SLCO1A2, SLC22A5, and ABCC4 genes only have been assumed to be good candidates for 
imatinib absorption [96]. We also analysed polymorphisms in these three genes with interesting 
results. In particular, the minor alleles in SLC22A5 rs2631367 and rs2631372 were associated with 
prolonged TTP. As far as we know, none of these two polymorphisms has ever been investigated in 
any pharmacogenetic study related to imatinib, making it mandatory to validate this observation in 
independent data sets (GIST as CML as well). With regard to the ABCC4 gene - also not 
investigated in previous pharmacogenetics studies – of the two investigated polymorphisms, the 
rs9561765 variant resulted marginally associated with a prolonged TTP. Unfortunately, due to the 
sample size, we had limited power to detect modest effects, as well as concrete possibility of 
detecting apparent correlations by chance. However, given the function assigned to the SLC22A5 
and ABCC4 genes in imatinib absorption, this finding is biologically plausible, and further in vitro
studies assessing the functional significance of this polymorphisms are warranted. 
Interestingly, none of the ABCB1 investigated polymorphisms have been associated to TTP. Three 
variants have been extensively studied in the literature - rs2032582, rs60023214 and rs1128503 - 
both individually and as a haplotype in CML patients and the results have been inconsistent. Kim 
and colleagues [94] found no association between ABCB1 genotypes/haplotypes and imatinib 
efficacy. On the other hand we found a weak association between ABCB1 CC carriers (rs60023214) 
only in a subset of Caucasian CML patients, which is consistent with the finding of Angelini and 
colleagues [79]. These results, although controversial, suggest a role of the ABCB1 gene in 
determining response to imatinib in CML patients. It remains to elucidate which is the causal 
variant, and the importance in GIST patients. 
The correlation between polymorphisms in members of the OCTN family transporters and imatinib 
efficacy might be very important in relation to the use of imatinib in the adjuvant setting. Currently, 
the optimal adjuvant treatment duration and the optimal patients’ selection remain the subjects of 
extensive researches 
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 [97]. Recently, Joensuu reported that three years of adjuvant imatinib substantially improves the 
disease-free survival and overall survival of patients with a high risk of recurrence, compared with 
one year [98]. However, among these patients the observed rate of recurrence is quite low (20-
30%), which makes the identification of pharmacokinetic markers useful for a further sub-
classification of the patients. This may be very important to identify patients that might benefit from 
intervals longer than three years. 
Conclusion (I) 
Imatinib has offered unprecedented improvements in GIST treatments. KIT/PDGFRα mutational 
status or acquisition of secondary mutation is a common mechanism, however not the unique, of 
imatinib resistance. The heterogeneity in mechanisms of secondary resistance unquestionably 
highlights  the need of biomarkers of efficacy. Thus, collecting data on the role of polymorphisms 
in imatinib response, at the moment scarce in CML patients and unavailable in GIST, represents a 
clinical priority. Our study identified polymorphisms in imatinib transporters genes SLC22A4 and 
SLC22A5 that improved time to progression, suggesting that genotyping should be taken into 
account in an attempt to individualize GISTs treatment, representing an attractive opportunity for 
new clinical trials. 
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II. Folate-related polymorphisms in GIST: susceptibility and 
correlation with tumor characteristic and clinical 
outcome 
A recent finding suggests that the DNA methylation profile may be associated with aggressive 
clinical behavior and unfavorable prognosis in gastrointestinal stromal tumor (GIST) [99]. 
However, as far as we are aware, there have been no investigations exploring the influence of 
genetic polymorphisms in enzymes that take part in the folate metabolic pathways GIST. 
Materials and methods 
Study population - A total of 60 unresecTable/metastatic GIST patients were retrospectively 
enrolled in this study. Thirty-two patients were enrolled at Sant’Orsola-Malpighi Hospital, Bologna, 
and 28 at Istituto Nazionale dei Tumori, Milan, Italy. Clinical information was collected 
retrospectively from the patients’ medical records. Overall survival (OS) was defined as the time 
from the first day of treatment to death from disease. Dates of death were obtained and cross-
checked using the inpatient medical records. If a patient was alive, OS were censored at the time of 
the last follow-up. For the 54 patients on standard first-line imatinib therapy time to progression 
(TTP) was calculated from the start of imatinib therapy to the date of disease progression 
documented by the CT scan performed approximately every 3-4 months. Data for patients who did 
not progressed at the last follow-up TTP evaluation were censored at that time. In order to exclude 
disease susceptibility we also genotyped 153 controls, anonymous blood donors from the Centro 
Trasfusionale, Sant’Orsola-Malpighi Hospital, Bologna. The study was approved by the Ethics 
Committees of the two institutions. The analysis was done after written informed consent for study 
participation and anonymous data publication in accordance with national legislation. Any subjects 
could cancel participation at any time during the study, according to Helsinki Declaration and later 
Amendments. 
Genotyping analysis - We selected thirteen common [minor allele frequency (MAF) > 0.05 in 
Caucasian], well-studied functional variants - located in regulatory region, cause non-synonymous 
amino acid changes and/or have been repeatedly associated with cancer risk, survival or treatment 
response. Patients with available peripheral blood were eligible for this retrospective study. DNA 
was isolated as previously described. Characteristics of the studied polymorphisms - two 
insertion/deletion, one tandem repeat and ten single nucleotide polymorphisms - are reported in 
Table 7. Genotypes were determined by PCR RFLP and RT-PCR as previously described. Positive 
and negative controls were included in each reaction as quality control. In addition, for internal 
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quality control (accuracy of genotyping) 90% of samples were repeated. The concordance between 
the original and the duplicate samples for all the analysed polymorphisms was 100%. 
Statistical analysis - The distribution of genotypes was tested for departures from the Hardy-
Weinberg equilibrium using the χ2 test. Survival analysis methods were used to examine the 
relationship between genotypes [homozygous wild-type, heterozygous and homozygous for the 
variant allele] and GIST time to progression. In univariate analysis, the survival curves were 
estimated and plotted with the Kaplan-Meier method. The curves were compared with log-rank test 
of equality of survivor functions (statistical significance defined as p < 0.05). In multivariate 
analysis, hazard ratios (HR) and 95% confidence interval (95% CI) were estimated with Cox 
proportional hazards models, using gender, age, and status (localised/metastatic) at diagnosis, as 
covariates in addition to the genotype. The proportional hazards assumption was tested (P > 0.05) 
using Schoenfeld residuals. Multiple logistic regression was used to assess the relation between 
individual polymorphisms and primary resistance. Statistical analysis was conducted using Stata 
Intercooled version 12.0. 
Table 7. SNPs description 
Gene [full name; Protein name]   SNP ID METHOD [A]  
RFC [Reduced folate carrier 1] 
rs1051266 [Arg27His] RFLP[Shimasaki et al.,2006]98
FOLR [Folate receptor 1] 
rs2071010 [5’ UTR] 
RT TaqMan assay C_15861044_10 
DHFR [Dihydrofolate reductase ] 
rs70991108 [19bp ins/del;Intronic] RFLP [Johnson et al., 2004] 99
MTHFR [Methylenetetrahydrofolate reductase] 
rs1801133 [Ala222Val]] 
RFLP [Sanyal et al., 2004] 100
rs1801131 [Glu429Ala]
RFLP [Sanyal et al., 2004] 100
MTR [Methionine synthase] 
rs1805087 [Asp919Gly] 
RT TaqMan assay C_12005959_10
MTRR [Methionine synthase reductase]
rs1801394 [Ile49Met] 
RT TaqMan assay C_3068176_10 
rs1532268 [Ser175Leu] 
RT TaqMan assay C_3068164_10 
rs162036 [Lys350Arg] RT TaqMan assay C_3068152_10 
rs10380 [His595Tyr] 
RT TaqMan assay C_7580070_1 
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SHMT [Serine hydroxymethyltransferase ] 
rs1979277 [Leu474Phe] 
RT TaqMan assay C_3063127_10 
TYMS [Thymidylate synthase] 
rs45445694 [6bp ins/del; enhancer region] RFLP [Skibola et al, 2002] 
101
rs34489327 [28bp tandem repetition; 
3’- near gene] 
RFLP [Skibola et al, 2002] 101
[A] RT = Real-Time PCR with TaqMan allelic discrimination assay [Applera, Foster City, USA]; 
    RFLP = PCR-RFLP and M = Multiplex PCR, analysis carried out according to published 
methods [reference parenthetically] or as standardized in our laboratory (primer set, T (°C) of 
annealing and restriction enzymes (Fermentas, Vilnius Lithuania) described]. 
Results 
Characteristics of the study population. The cohort of 60 Caucasian GIST patients (Table 8) was 
made up of 65% men and 35% women (median age at diagnosis 58.0 years; range 18-83 years). The 
most common primary sites were the stomach (55.0%) and the small intestine (40.0%); the 
remaining 5%, the sites of onset were oesophagus (1 case) and rectum (2 cases).  
Table 8. Patient and disease characteristics of the studied populations. 
Cases (n = 60) Controls (n = 153) 
Gender, n (%) 
    Female 21 (35.0%) 61 (39.9%) 
    Male 39 (65.0%) 92 (60.1%) 
Age at diagnosis or selection, years
    median (range) 58.0 (18-83) 47 (21-79) 
Tumour site, n (%) 
    Stomach 33 (55.0%)  
    Small Intestine 24 (40.0%)  
    Other 3 (5.0%)  
Tumour size, n (%) 
    ≤ 2 cm 1 (1.6%) 
    2 - 5 cm 6 (10.0%) 
    5 - 10 cm 18 (30.0%) 
     10 cm 22 (36.7%) 
    Missing 13 (21.7%) 
Mitotic index , n (%)  
    < 5  13 (21.7%) 
    6-10 5 (8.3%) 
     10 17 (28.3%) 
    Missing 25 (41.7%) 
Mutational status, n (%) 
    KIT exon 11 35 (58.3%) 
    PDGFR/KIT WT 9 (15.0%) 
    Other than PDGFR D842V and 
PDGFR/KIT WT 
4 (6.7%) 
   Missing 
12 (20.0) 
 50 x High power filed. 
§ Numbers for certain variables may not add up to the total number because of missing information. 
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Twenty-three patients (38.3%) had metastatic disease, with liver and peritoneum as the most 
common sites of metastases. Thirty-five patients (58.3%) harboured KIT exon 11 mutations, while 
only one patient had a KIT exon 9 mutation. Three patients (5.6%) had a PDGFR mutation, 
excluding the D842V, and nine (15.0%) were KIT/PDGFR WT GISTs. In twelve GISTs, 
mutational status was unknown, due to insufficient or unavailable biological material for the 
analysis. Control group (n = 153) was made up of 60% men and 40% women (median age 47 years, 
range 21-79 years).
Genotypes distribution in the two studied populations. Genotype frequencies of the thirteen 
polymorphisms were found to be in Hardy-Weinberg equilibrium (P > 0.05) in both patients and 
controls, with the exception of rs1801133 in the MTHFR genes in controls only (P = 0.016). MAF 
and Hardy-Weinberg equilibrium P value are presented in Table 9. 
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Table 9. Allele frequency 
 Genotypes distribution n   
 wt HE SNP Frequency 
variant allele
P HWE
RFC – rs1051266
Cases 21 31 7 q = 0.381 0.383 
Controls 59 64 29 q = 0.401 0.127 
FOLR – rs2071010
Cases 51 6 0 q = 0.053 0.675 
Controls 131 20 1 q = 0.072 0.805 
DHFR – rs70991108
Cases 22 31 6 q = 0.364 0.302 
Controls 60 69 24 q = 0.382 0.576 
TS – rs45445694
Cases 11 33 16 q = 0.542 0.404 
Controls 38 66 49 q = 0.536 0.100 
TS – rs34489327
Cases 25 24 4 q = 0.301 0.588 
Controls 54 65 34 q = 0.435 0.094 
SHMT – rs1979277
Cases 27 30 3 q = 0.300 0.140 
Controls 85 55 10 q = 0.250 0.785 
MTHFR - rs1801133
Cases 22 28 10 q = 0.400 0.830 
Controls 36 91 26 q = 0.467 0.016 
MTHFR - rs1801131
Cases 24 28 8 q = 0.367 0.976 
Controls 84 57 12 q = 0.264 0.595 
MTR - rs1805087
Cases 40 18 2 q = 0.183 0.988 
Controls 101 48 4 q = 0.183 0.543 
MTRR - rs10380
Cases 51 9 0 q = 0.075 0.530 
Controls 121 30 1 q = 0.105 0.556 
MTRR – rs162036 
Cases 47 11 1 q = 0.110 0.706 
Controls 112 38 2 q = 0.138 0.539 
MTRR – rs1801394 
Cases 21 30 9 q = 0.400 0.747 
Controls 56 64 33 q = 0.423 0.075 
MTRR - rs1532268 
Cases 26 25 9 q = 0.358 0.467 
Controls 66 66 21 q = 0.353 0.492 
Details of the results of association tests for each genetic polymorphism chosen for analysis in our 
case-control study population are presented in Table 9 and 10. The most significant result was 
found for the 6bp ins/del in TS gene (rs34489327). In particular the allele with the 6bp deletion was 
significantly less common in cases compared to controls (30.2% vs 43.5%; OR 1.84, 95% CI 1.29-
3.01; P = 0.014 Tab 9). Genotype analysis also showed a similar significant association (P = 0.019) 
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with the 6bp del/del genotype less frequent in cases compared to controls (7.5% vs 22.2%). There 
was no significant difference in genotype distribution or allele frequencies between cases and 
controls for any of the other polymorphisms tested across the key enzymes that take part in the 
folate metabolic pathways. 
Association between genetic polymorphisms and clinical features at diagnosis. Results of the 
associations of each genotype and clinical variables are presented in Tables 11 (RFC, FOLR, 
DHFR, TS, SHMT and MTHFR). Univariate analysis showed an excess of wild-type MTR - 
rs185087 - genotype in patients aged less than 60 years when compared with those over 60 (84.6% 
vs 51.5; P = 0.008), and in patients with mitotic index greater than 10, compared to patients with 
lower mitotic index (88.2 vs 55.6; P = 0.032). In addition an excess of wild-type RFC, FOLR and 
MTHFR (rs1801130) genotypes was observed in patients with tumor size greater than 10 cm, 
compared to patients with smaller tumor. 
With regard to mutational status, we divided the patients in three groups – KIT or PDGFRA 
mutated and wt GIST. Results of the associations of each genotype and mutational status are 
included in Tables 11 (RFC, FOLR, DHFR, TS, SHMT and MTHFR). According to this 
stratification, we observed an excess of wild-type RFC genotype in patients with PDGFRA 
mutations compared to KIT mutated and wild-type GIST (100% vs 37.1% and 11.1% respectively; 
P 0.021). We also observed that the TS 2R2R genotype (rs45445694) was more represented in 
PDGFRA mutated patients compared to KIT mutated and wild-type GIST (66.7% vs 16.7% and 0% 
respectively; P = 0.027). Another finding was an excess of the presence of at least a variant MTRR 
rs10380 allele in wild-type GIST compared to KIT/PDGFRA mutated patients (33.3% vs 2.8% and 
0% respectively; P = 0.011). The same finding was seen for MTRR rs162036 (44% vs 8.6% and 0% 
respectively; P 0.020). A borderline association was also seen for MTHFR (rs1801133) genotype. 
In particular we observed an excess of the wild-type genotype in PDGFRA-mutated and wild-type 
GIST compared to KIT-mutated patients (66.7% both vs 27.8%; P = 0.055). 
Association between time to progression and genetic polymorphisms. Fifty-four patients received 
standard first-line imatinib 400 mg daily, with a median duration of imatinib administration of 36,9 
months. Demographic and disease characteristic of the subgroup of GIST has been extensively 
previously described. Regarding imatinib response, the best results during therapy were partial 
response and sTable disease in 90.7%. With a median follow-up of 36.9 months, progression of 
disease was observed in 26 cases (48.1%), with a median TTP of 21.8 (range: 1.6-58.2). 
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In the univariate analysis, we observed that the presence of the variant allele RFC rs1051266 - in 
homozigosity is associated, at the limit of statistical significance, with a reduced risk of disease 
progression (HR 0.144, 95% CI 0.019 – 1.07; P = 0.059). The relationship resulted significant after  
type allele in RFC (AA/AG), was associated with reduced TTP (P = 0.028; Figure 16). None of the 
other analysed SNPs correlated with the progression. Noteworthy, none of the five patients with  
correction for gender, age, and status at diagnosis (HR 0.107, 95% CI 0.014-0.82; P = 0.032). 
Alleles were correlated with TTP based on the Kaplan-Meier method. Presence of at least one wild- 
heterozygote FOLR genotype showed progression. 
.   Figure 16. Kaplan-Meier estimated. Presence of at least one wild-type allele in RFC (AA/AG), was 
associated with reduced TTP. 
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Table 10. RFC, FOLR, DHFR, TS, SHMT and MTHFR genotype frequencies according to clinical features. 
FOLR rs2071010 DHFR rs70991108 
19bp Ins/del
TS rs45445694  
28bp repeat
TS rs34489327 
6bp Ins/del
SHMT rs1979277 MTHFR rs1801130 MTHFR rs1801133
AA AG/GG +/+  +/-_-/- 2R2R 2R3R/3R3R 6 +/+ 6 +/-_-/- CC CT/TT
22 (68.8) 28 
(90.3) 
3 
(9.7) 
10 
(31.3) 
22 
(68.7) 
6 
(18.2) 
27 
(81.8) 
15 (48.4) 16 (51.6) 16 (48.5) 17 (51.5) 13 (39.4) 20 (60.6) 15 (45.5) 18 (54.5) 
15 (57,7) 23 
(88.5) 
3 
(11.5 
11 
(42.3) 
15  
57.7) 
5 
(19.2) 
21 
(80.8) 
10 (45.5) 12 (54.5) 11 (40.7) 16 (59.3) 8 
(30.8) 
18 (69.2)   9 (34.6) 17 (65.4) 
0.082 0.384 0.918 0.695 0.441 0.492 0.400 
        
13 (65.0) 20 
(95.2) 
1 
(4.8) 
  7 
(33.3) 
14 
(66.7) 
3 
(14.3) 
18 
(85.7) 
  9 (47.4) 10 (52.6) 11 (52.4) 10 (47.6) 5 (23.8) 17 (43.6)   8 (38.1) 13 (61.9) 
25 (64.1) 31 
(86.1) 
5 
(13.9) 
15 
(39.5) 
23 
(60.5) 
8 
(20.5) 
31 
(79.5) 
16 (47.1) 18 (52.9) 16 (41.0) 23 (59.0) 16 (76.2) 22 (56.4) 16 (41.0) 23 (59.0) 
0.279 0.641 0.552 0.983 0.399 0.129 0.825 
        
18 (54.5) 27 
(84.4) 
5 
(15.6) 
15 
(45.4) 
18 
(54.5) 
6 
(18.2) 
27 
(81.8) 
13 (46.4) 15 (53.6) 18 (54.5) 15 (45.4) 12 (36.4) 21 (63.6) 12 (36.4) 21 (63.6) 
18 (75.0) 22 
(100) 
0   5 
(21.7) 
18 
(78.3) 
5 
(20.8) 
19 
(79.2) 
11 (50.0) 11 (50.0)   8 (33.3) 16 (66.7)   9 (37.5) 15 (62.5)   9 (37.5) 15 (62.5) 
  2 
(66.7) 
1 
(33.3) 
  2 
(66.6) 
1 
(33.3) 
0   3 
(100) 
  1 (33.3)   2 (66.7)   1 (33.3)   2 (66.7)   1 (33.3)   2 (66.7)   3 
(100) 
  0 
0.077 0.109 0.679 0.858 0.259 0.989 0.093 
        
19 (76.0) 18 
(78.3) 
5 
(21.7) 
  7 
(29.2) 
17 
(78.8) 
3 
(12.0) 
22 
(88.0) 
  9 (39.1) 14 (60.9) 14 (56.0) 11 (44.0)   5 (20.0) 20 (80.0) 13 (52.0) 12 (48.0) 
  9 (42.9) 21 
(100) 
0   9 
(40.9) 
13 
(59.1) 
5 
(22.7) 
17 
(77.3) 
10 (58.8)   7 (41.2)   9 (40.9) 13 (59.1) 12 (54.5) 10 (45.5)   6 (27.3) 16 (72.7) 
0.023 0.404 0.329 0.218 0.302 0.014 0.085 
                
12 (66.7) 13 
(76.5) 
4 
(23.5) 
  5 
(29.4) 
12 
(70.6) 
2 
(11.1) 
16 
(88.9) 
  5 (31.2) 11 (68.8) 11 (61.1)   7 (38.9)   4 (22.2) 14 (77.8)   6 (33.3) 12 (66.7) 
10 (58.8) 16 
(94.1) 
1 
(5.9) 
  8 
(47.1) 
  9 
(52.9) 
3 
(17.6) 
14 (82.3) 7 (50.0)   7 (50.0)   9 (52.9)   8 (47.1)   8 (47.1)   9 (52.9)   6 (35.3) 11 (64.7) 
0.146 0.290 0.581 0.296 0.625 0.122 0.903 
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22 (62.9) 30 
(90.9) 
3 (9.1) 17 
(48.6) 
18 (51.4) 6 
(16.7) 
30 (83.3) 14 (46.7) 16 (53.3) 16 (44.4) 20 (55.6) 16 (44.4) 20 (55.6) 10 (27.8) 26 (72.2) 
  0   3 
(100) 
0   1 
(33.3) 
  2 (66.7) 2 
(66.7) 
  1 (33.3)   2 
(100) 
  0   2 (66.7)   1 (33.3)   1 (33.3)   2 (66.7)   2 (66.7)   1 (33.3) 
  8 (88.9)   9 
(100) 
0   1 
(11.1) 
  8 (88.9) 0   9 (100)   4 (44.4)   5 (55.6)   3 (33.3)   6 (66.7)   1 (11.1)   8 (88.9)   6 (66.7)   3 (33.3) 
0.557 0.120 0.027 0.320 0.593 0.179 0.055 
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Association between overall survival and genetic polymorphisms. The genotype distribution of the 
thirteen polymorphisms in genes coding for the key enzymes of the folate metabolic pathways and 
the association with OS are summarized in Table 12. Compared with the homozygote SHMT1 CC 
genotype, the TT genotype was significantly associated with a hazard of early death in the 
univariate analysis (HR = 6.53, 95% CI 1.17 – 36.36; P = 0.032). After a multivariate adjustment 
for gender, age, and status at diagnosis only a tendency for statistical significance of early death was 
obtained (HR = 4.53, 95% CI 0.77 – 26.58; P = 0.095). Interestingly, of the five patients with 
heterozygote FOLR genotype none experienced mortality. None of the other analyzed 
polymorphisms showed an association with the OS. 
Table 12. Univariate and multivariate analyses of the different genotypes and OS in GIST patients. 
Genotypes Patient
N 
Event 
n 
Crude  
HR (95% CI) P § 
Adjusted 
HR (95% CI) P #§
RFC rs1051266
AA 21 7 1.  1.  
AG 28 6 0.52 (0.17 – 1.55) 0.239 0.70 (0.22 – 2.22) 0.548 
GG 7 1 0.22 (0.03 – 1.78) 0.155 0.35 (0.04 – 3.24) 0.353 
FOLR rs2071010
AA 48 12 - - - - 
AG/GG 5 0 - - - - 
DHFR rs70991108 
19 +/+ 21 5 1.  1.  
19 +/- 30 6  0.99 (0.30 – 3.26) 0.983 0.94 (0.30 – 3.19) 0.925 
19 -/- 5 2 2.01 (0.40 – 10.83) 0.389 1.40 (0.26 – 8.74) 0.718 
TS – rs45445694
2R2R 11 1 1.  1.  
2R3R 30 6 1.48 (0.18 – 12.36) 0.717 1.57 (0.19 – 13.23) 0.677 
3R3R 16 7 3.93 (0.48 – 32.01) 0.201 3.63 (0.44 – 30.09) 0.232 
TS rs34489327
6 +/+ 24 5 1.  1.  
6 +/- 22 3 0.39 (0.091 – 1.67) 0.205 0.30 (0.065 – 1.40) 
6 -/- 4 2 1.94 (0.94 – 10.25) 0.436 1.38 (0.24 – 8.04)  
SHMT rs1979277
Table 11. Most relevant results correlation between mutational status and candidate genotypes. 
n (%) 
RFC rs1051266 TS rs45445694  
28bp repeat
MTHFR rs1801133 MTRR rs10380 MTRR rs162036
           
Mutational 
status
          
KIT 13 (37.1) 22 (62.9) 6 (16.7) 30 (83.3) 10 (27.8) 26
(72.2) 
35 (97.2) 1 
(2.8) 
32 (91.4)   3 
(8.6) 
PDGFRA   3 (100)   0 2 (66.7)   1 (33.3)   2 (66.7)   1 (33.3)   3 (100) 0 3 
(100) 
0 
wt   1 (11.1)   8 (88.9) 0   9 (100)   6 (66.7)   3 (33.3)   6 (66.7) 3 
(33.3) 
5 (55.6) 4 
(44.4) 
P- value 0.021 0.027 0.055 0.011 0.020 
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CC 25 4 1.  1.  
CT 29 8 1.73 (0.52 – 5.75) 0.374 2.01 (0.59 – 6.83) 0.266 
TT 3 2 6.53 (1.17 – 36.36) 0.032 4.53 (0.77 – 26.58) 0.095 
MTHFR rs1801133
CC 20 5 1.  1.  
CT 28 8 1.00 (0.33 – 3.08) 0.995 0.99 (0.31 – 3.18) 0.988 
TT 9 1 0.41 (0.048 – 3.50) 0.414 0.46 (0.053 – 3.99) 0.479 
MTHFR rs1801131
AA 22 6 1.  1.  
AC 28 7 0.97 (0.33 – 2.90) 0.957 0.93 (0.27 – 3.22) 0.911 
CC 7 1 0.56 (0.066 – 4.57) 0.579 0.40 (0.048 – 3.35) 0.398 
MTR rs1805087
AA 37 11 1  1.  
AG 18 3 0.55 (0.15 – 1.97) 0.356 0.55 (0.15 – 2.01) 0.363 
AG/GG 20 3 0.53 (0.15 – 1.90) 0.331 0.54 (0.15 – 1.99) 0.355 
MTRR rs10380
CC 49 13 1.  1.  
CT/TT 8 1 0.36 (0.047 – 2.77) 0.328 0.43 (0.056 – 3.34) 0.421 
MTRR rs162036
AA 44 10 1.  1.  
AG/GG 12 3 0.89(0.24 – 3.24) 0.856 1.04 (0.29 – 3.80) 0.953 
MTRR rs1801394
AA 20 6 1.  1.  
AG 29 7 0.83 (0.28 – 2.47) 0.737 0.88 (0.29 – 2.65) 0.814 
GG 8 1 0.29 (0.035 – 2.42) 0.252 0.33 (0.037 – 2.90) 0.315 
MTRR rs1532268 
AA 20 6 1.  1.  
AG 28 7 0.83 (0.28 – 2.47) 0.737 0.49 (0.13 – 1.86) 0.291 
GG 8 1 0.29 (0.035 – 2.42) 0.252 1.45 (0.36 – 5.79)  0.600 
Discussion
To the best of our knowledge this is the first study to investigate the association between tumors 
characteristics and clinical outcomes and potentially functional polymorphisms in genes of the 
folate pathway in GIST patients. Genetic approaches to define mechanisms of GIST development, 
with the recognition of KIT/PDGFRA mutation as key player, have delivered meaningful insights 
in the development of treatment strategies. Nevertheless, imatinib remains the only first-line 
treatment approved, even in patients for whom we might anticipate a lack or a subsequent failure of 
efficacy [64]. In addition, the mechanisms of refractoriness or resistance, in addition to the 
acquisition of secondary mutations in known KIT and PDGFRA exons, remains still unknown in 
most patients [68]. We now recognize the enormous scope of genetic variation among humans, 
which can be used to probe the genetics of treatment response and disease susceptibility. Basically 
all genes are subject to genetic variability, which can be associated with the altered efficiency of a 
biological pathway. These genetic variations can be associated with a person's risk for developing 
cancer as a result of environmental exposures, as well as variability in drug response. Genetic 
polymorphisms in xenobiotic/drug metabolizer, transporters and targets loci were a natural starting 
point to study their relevance in susceptibility and treatment efficacy. Besides these, the biological 
components that may also influence susceptibility and therapies outcome include enzymes that 
repair DNA damage, factors that regulate cell cycle control, cell division and cell death, and 
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enzyme involved in the immune response [104]. Many findings support the idea that different 
mechanisms may be involved in the GIST tumorigenesis processes, as emphasized by the widely 
different clinical behavior of each GIST patient, regardless of the KIT/PDGFRA mutational status. 
In this regard we thought that polymorphisms in candidate genes related to the folate metabolism 
may be a good choice for investigating association with clinic-pathological features, response to 
treatment and survival. Due to the role of these genes in DNA synthesis, DNA repair and DNA 
methylation, it is plausible that genetic variants of these genes may influence their function, 
resulting in aberrant methylation or DNA synthesis inhibition. These modifications may be thus 
involved in the tumor progression and consequently may play a relevant role in the long term 
outcome of patients. In the present study we investigated the frequencies of selected polymorphisms 
in patients stratified by age, gender and other main molecular and clinical characteristics, and found 
that few genotypes may show a likely correlation. However, the most remarkable results are the 
association with disease risk, TTP and OS. In particular, we found evidence for an association 
between a polymorphism in the TS gene (rs34489327) and GIST susceptibility. The TS gene 
product, a folate dependent enzyme, works converting dUMP to dTMP, which is responsible for 
thymine incorporation during DNA-synthesis [105]. The rs34489327 is a 6bp ins/del in the 3’- UTR 
region, and together with rs34743033, located in the 5’-UTR region, is the most extensively 
reported TS variant. These two variants are associated with the occurrence of various tumors, such 
as colorectal cancer, lymphoma, and acute lymphocytic leukemia [105-107]. The 6bp deletion 
polymorphism has been associated with a decreased protein expression due to an effect on 
secondary mRNA structure or mRNA stability [108,109]. Since the polymorphism has been linked 
to a reduced enzymatic activity, and considering its critical function we would hypothesized that the 
TS 6bp del may be associated with a higher cancer risk. TS inhibition results in depletion of 
deoxythymidine triphosphate (dTTP) pools followed by thymine-less death or, in some instances, 
high levels of uracil mis-incorporation in DNA followed by extensive repair and subsequent 
double-strand breaks in DNA, that promote chromosomal instability, translocations, and aberrations 
[110]. Interestingly, the TS 6bp deletion was found more frequently in the healthy controls, 
indicating a lower risk associated with the variant allele. Given the small population size, yet 
similar to other studies reported in the literature, due to the rarity of the tumor, we cannot exclude 
that the association we found is chance. Nevertheless, we should consider that the findings of other 
studies on cancer risk are controversial, with both positive, negative or null results [110-114]. 
Different hypothesis has been proposed to explain the observed discrepancies. It might reflect 
differences in the gene-disease association (i.e. different types of cancer, different association) or 
may reflect different intakes of micronutrients, folate and B vitamins in particular, in the different 
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populations [115-117]. Another alternative explanation is that TS requires 5,10-
methylenetetrahydrofolate (5,10-MTHF) as a cofactor, and competes with MTHFR for available 
5,10-MTHF. The TS-mediated reaction is closely linked to the reaction catalyzed by MTHFR, this 
implies a narrow interplay between these two enzymes. Therefore, addressing only polymorphisms 
in one gene may be an oversimplification of the reality and this prompted us to also include genetic 
polymorphisms in the key enzymes that take part in the folate metabolic pathways. However, none 
of the other investigated variants were associated with a higher risk of GIST. It should be noted that 
a better and meaningful approach would have been the gene–gene interactions analysis. Though, 
this approach is not practicable in our study, as it will necessarily suffer of insufficient statistical 
power due to the small sample size. 
Through our multiple candidate gene approach, we found that polymorphisms in RFC and FOLR 
genes may be associated with TTP, although only RFC reached statistical significance. To us this 
finding is intriguing, as both the gene products are involved in the folic acid and reduced folates, as 
the 5’-Methyltetrahydrofolate (5’-MTHF) cellular uptake and distribution. In particular, RFC has a 
higher affinity for reduced folates, vice versa FOLR has higher affinity for folic acid [118,119]. 
With regard to RFC, previous studies have shown that individuals with the A allele, which is found 
significantly associated with reduced TTP in our study, had reduced plasma levels of folates and 
homocysteinemia than individuals carrying the G allele [120,121]. Dietary intake of folate has been 
associated with reduced risk for a number of cancers [122-124]. The proposed mechanisms are 
suboptimal DNA methylation and DNA repair capacity. Among them, altered cytosine methylation 
in DNA, referable to folate deficiency, may lead to inappropriate activation of proto-oncogenes and 
induction of malignant transformation [125]. Therefore, it is plausible that the RFC genotype may 
be involved in GIST tumorigenesis, by affecting plasma folate and homocysteine levels. 
Advances in molecular biology have highlighted that epigenetic modifications may play important 
roles in tumorigenesis and tumor progression. The different methylation status of several genes has 
been associated with different tumor phenothypes and clinical behaviors in quite a few cancer 
[126]. Recently few studies have reported aberrant methylation status in GIST patients, particularly 
those KIT/PDGFRA wild-type [127,128]. Since methylation status of various genes greatly 
influences the diagnosis and prognosis of several tumors, it is reasonable to think that genetic 
polymorphisms in key enzymes of the folate metabolism, may perturb this pathway and have the 
potential of becoming biomarkers of prognosis. To explore this hypothesis, we investigated the 
association of the selected genetic polymorphism with OS. Among all, only the SHMT variant 
resulted associated with OS. SHMT is a vitamin B6-dependent SHMT1 enzyme that catalyzes the 
reversible conversion of serine and tetrahydrofolate to glycine and 5,10-MTHF in the cytoplasm for 
First objective: SNP genotyping in GIST patients treated with imatinib 

49
the synthesis of methionine, thymidylate, and purines. The C variant, associated to reduced OS in 
our population, has been associated to reduced folate levels [129,130], thus the polymorphism could 
mimic a situation of folate deficiency by limiting the availability of one-carbon units for both 
remethylation of homocysteine, important for DNA methylation, and DNA synthesis. The 
importance of folate status is supported by the evidence that none of the patients with heterozygous 
FOLR genotypes showed progression or experienced mortality. However, it must be stressed that 
overall survival may be affected by multiple variables, and the potential prognostic role of the 
folate-genotype should be verified in a larger sample size stratified according to the molecular and 
clinical features and the medical treatment received. 
Conclusion (II)
To conclude, we report significant association between genetic polymorphisms in key enzymes of 
the folate metabolic pathways and GIST tumorigenesis, clinical features and outcome. Our finding 
should be considered in the context of both the strengths – the investigation of a large number of 
polymorphisms across genes with well-defined roles in the folate pathway and the robust 
genotyping protocols - and limitations – the small sample size - and should be viewed as 
exploratory. On the other hand, the rarity of GIST requires that promising genetic polymorphisms, 
such as those reported in the present study are subjected to further investigation. In particular, these 
results need to be further confirmed in larger independent studies, which will allow genome-wide 
association studies - only feasible when large cohort of patients is available – opening up the 
opportunity to identify new loci associated with GIST susceptibility and/or clinical outcome, or to 
definitively confirm the role of candidate genetic variations. Furthermore, the enrichment of the 
study by having available serum folate levels or dietary intake, associated with the opportunity of 
gene-gene and gene-environment interaction analysis, may lead to a better understanding of GIST 
pathogenesis, clinical manifestation and disease course. 
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Figure 17. Main key players in KIT downstream signaling pathway.
Figure 17 highlights the main players in the KIT downstream players that will be widely discuss 
below. 
Clinical progression of GIST, during TKI therapy, is often multifocal. However, TKI resistance 
mutations have been assessed in only single, or few, progressing metastases per patient, so that the 
heterogeneity of these mutations, in a given patient, remains unclear [131]. 
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We screened up to 46 progressing GIST metastases per patient to evaluate TKI resistance 
mechanisms, part of a more extensive project aimed to characterize the secondary resistance by 
means of high-throughput screens. 
Materials and methods 
Patients - We analyzed a total of 14 GISTs patients (9 males, 5 females, age range 32-73, median 
age 55). All patients progressed clinically on imatinib or sunitinib, according to the conventional 
Southwest Oncology Group/Response Evaluation Criteria in Solid Tumours. All the patients 
underwent resection during 2002–20012 at the Brigham and Women's Hospital, Boston, MA, USA. 
Imatinib or sunitinib was discontinued within 1 week prior to debulking surgeries. This study was 
approved by the Institutional Review Board of Brigham and Women's Hospital.  
Haematoxylin and eosin-stained sections from paraffin blocks were reviewed by pathologists to 
confirm the diagnoses prior to inclusion in the study. Tumour regions from different metastases or 
different areas within metastases were selected from each patient, with an emphasis on variation in 
tumour cytology, KIT expression (KIT-positive or KIT-negative) and mitotic activity. all frozen 
tumor specimens were analyzed histologically, and shown to be composed of > 90% neoplastic 
cells. 
The morphological appearance (spindle cell, epithelioid cell, mixed cell type, unusual morphology), 
tumour size, location, treatment effects (necrosis, hyalinosis, pseudo-chondroid changes, 
haemorrhage) were evaluated, as well as mitotic rate [expressed as the number of mitotic Figures 
per 50 high power fields (HPFs) in the most mitotic area, using a × 40 objective and a × 10 ocular, 
field size 0.25 mm
2
]. 
For every patient we had from a minimum of 3 different metastases samples to up to 52 (Table 14). 
DNA samples. Genomic DNA was isolated, from frozen specimens, using QIAmp kit from QIagen 
(TurnberryLane Valencia CA, USA). All known precautions were observed during the DNA 
isolations to prevent cross-contamination between different samples. The extracted DNA was 
quantified using NanoDrop spectrophotometer (Thermo Scientific, Fisher Scientific, Pittsburgh, 
PA, USA). mutational analysis was performed on the extracted genomic DNA, using polymerase 
chain reaction with specific primer sets for KIT exons 9, 11, 13, 14, 15, 16, 17, 18 (Table 13). DNA 
were amplified in 20-l PCR reactions for 2 minutes at 94°C, followed by 30 seconds at 94°C, 30 
seconds minute at 60°C, and 1 minute at 72°C for 35 cycles, with a final step of 7 minutes at 72°C. 
PCR products were evaluated by ethidium bromide staining on a 1% agarose gel alongside 1 Kb 
Plus DNA Ladder (Invitrogen, Grand Island, NY, USA). The PCR products were purified using 
QIAquick PCR Purification Kit (QIagen), and Sanger sequenced. 
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Table 13. Primer sequences used for KIT mutational analysis. 
Exon Forward Reverse 
9 ATTTATTTTCCTAGAGTAAGCCAGGG ATCATGACTGATATGGTAGACAGAGC
11 CCAGAGTGCTCTAATGACTG CACAGAAAACTCATTGTTTCAGGTGG
13 ATTTTGAAACTGCACAAATGGTCCTT GCAAGAGAGAACAACAGTCTGGGTAA
14 GTAGCTCAGCTGGACTGATA AATCCTCACTCCAGGTCAGT 
16 GATCTGCCTGCAAGTTCACA GGCTCTAAAATGCTCTGTTCTCA 
17 GCGTACTTTTGATTTTTATTTTTGGTG AAATGTGTGATATCCCTAGACAGGATTT
18 CATTTCAGCAACAGCAGCAT CAAGGAAGCAGGACACCAAT 
Novel KIT mutations constructs. To evaluate if the secondary mutations were involved in the 
resistance we made KIT mutation 
constructs. Oligonucleotides 
representing various mutations were 
designed by the Stratagene online 
program and synthesized by 
Invitrogen. Wild type KIT or exon 9 
mutant KIT (A502_Y503dup) or 
exon 11 mutant KIT (V560D) was 
used as the template DNA for site-
directed mutagenesis reactions 
utilizing the mutant 
oligonucleotides and the 
QuikChange mutagenesis kit (Stratagene, Agilent Technology, 
Santa Clara, CA, USA, Figure 18). Successful mutagenesis was 
confirmed by sequence analysis of the whole coding sequence of 
KIT. 
The plamid chosen for the experiments was pCDNA 3.1 (Figure 
19) 
  
Figure 18. Overview of the site-directed mutagenesis method.
Figure 19. pcDNA plasmid.
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Functional experiments. Novel KIT mutations identified by sequencing were biochemically profiled 
using constructs prepared by site-directed mutagenesis. KIT autophosphorylation status was 
assessed by Western immunoblotting as described below. GIST48B cells, a cell line that has KIT 
gene but does not express KIT protein, were transiently transfected with mutated KIT constructs 
using the Lipofectamine Plus kit from Invitrogen. 24 hours after transfection, cells were exposed to 
different concentrations of imatinib, sunitinib (0.1, 0.5, 1 and 5 µmol\L). Whole-cell lysates were 
immunostained for p-KIT(Y721) and total KIT; p-KIT expression is inversely proportion to the 
drug cells response: the cells are responding to the treatment, have a lower expression of p-KIT.
Western blotting. Frozen tumor samples were diced in ice-cold lysis buffer containing protease 
inhibitors (10 mg/ml aprotinin, 10 mg/ml leupeptin, and 1mM phenylmethylsulfonyl fluoride), 
homogenized using a Tissue Tearor (Biospec Products, USA), and immunoblotted. Uniform protein 
transfer was demonstrated by Ponceau S staining (Sigma Chemical), and immunostains were 
performed for total KIT (Dako, #A4502, 1:500, rabbit) and phospoKIT (Cell Signaling, # 3391, 
1:500, rabbit); in the second part of the study, immunostains were performed, besides for KIT and 
phospo KIT, also for total MAPK (Cell Signaling, # 9102 1:1000, rabbit) for phospo-MAPK (Cell 
Signaling, # 9101, 1:1000, rabbit) for AKT (Cell Signaling, # 9272, 1:500, rabbit,) for phospo-AKT 
(Cell Signaling, # 9271, 1:500, rabbit); beta-actin (Sigma, #A4700, 1:500, mouse) was used as 
positive control. Detection was by chemiluminescence (ECL, Amersham Pharmacia 
Biotechnology), captured using a FUJI LAS1000-plus chemiluminescence imaging system. 
Clinically progressing KIT-mutant GISTs were from pts formerly responding to imatinib and/or 
sunitinib. KIT exons 8 through 18 were sequenced at 2000-fold coverage (454 pyrosequencing). As 
a part of this more extensive study, my work was focused on the confirmation and extension of 
these analyses, through Sanger sequencing, to additional metastases from the same patient. Drug-
response studies were performed by expressing mutant constructs in a KIT-negative GIST. 
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Age/Sex Metastases 
# 
Location Morphology Mitoses 
/10HPF 
Primary mutation Secondary 
mutation 
1 
2a 
2b 
3a 
3b 
4 
5 
6a 
6b 
7a 
7b 
7c 
7d 
7e 
7f 
7g 
7h 
8 
9a 
9b 
9c 
9d 
9e 
9f 
9g 
9h 
9i 
9l 
9m 
9n 
10 
11a 
11b 
11c 
abd wall 
periumbilicus 
periumbilicus 
periabd wall 
periabd wall 
periabd wall 
small bowel 
omentum 
omentum 
omentum 
omentum 
omentum 
omentum 
omentum 
omentum 
omentum 
omentum 
abd wall 
colon, spleen, upper quadrant 
colon, spleen, upper quadrant 
colon, spleen, upper quadrant 
colon, spleen, upper quadrant 
colon, spleen, upper quadrant 
colon, spleen, upper quadrant 
colon, spleen, upper quadrant 
colon, spleen, upper quadrant 
colon, spleen, upper quadrant 
colon, spleen, upper quadrant 
colon, spleen, upper quadrant 
colon, spleen, upper quadrant 
LUQ 
colon 
colon 
colon 
Spindle  
Spindle  
Spindle  
Spindle  
Spindle  
Spindle  
Mixed 
Spindle cells 
Spindle cells 
Spindle cells 
Spindle  
Epithelioid  
Epithelioid  
Short spindle 
Mixed 
Spindle  
Mixed 
Spindle  
Spindle  
Spindle  
Spindle  
Mixed 
Spindle  
Spindle  
Spindle  
Spindle  
Mixed 
Spindle  
Spindle  
Spindle  
N/A 
Mixed 
Spindle  
Mixed 
11:10 
9:10 
12:10 
7:10 
12:10 
12:10 
4:10 
8:10 
6:10 
12:10 
4:10 
14:10 
31:10 
16:10 
17:10 
19:10 
28:10 
15:10 
10:10 
20:10 
4:10 
25:10 
10:10 
28:10 
8:10 
14:10 
25:10 
16:10 
18:10 
18:10 
N/A 
10:10 
10:10 
20:10 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
Q575_P577delinsH 
S840N 
S840N 
None 
None 
S840N 
I571_D572delinsT 
S840N 
S840N 
S840N 
S840N 
I571_D572delinsT 
N822K 
S840N 
N822K 
S840N 
N822K 
N822K 
N822K 
N822K 
S840N 
N822K 
S840N 
N822K 
S840N 
S840N 
N822K 
N822K 
S840N 
N822K 
N822K 
N655S 
N822K 
N822K 
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12 
12 
14 
15a 
15b 
15c 
16a 
16b 
16c 
17 
18 
19 
20 
21a 
21b 
21c 
21d 
21e 
22(NL) 
lateral segment liver 
peritoneum 
small bowel 
Bladder 
Bladder 
Bladder 
Bladder 
Bladder 
Bladder 
pelvic 
pelvic 
pelvic 
small bowel 
Abd wall 
Abd wall 
Abd wall 
Abd wall 
Abd wall 
Spleen 
Spindle  
Spindle  
Short spindle 
Spindle  
Mixed 
Spindle  
Spindle  
Spindle  
Spindle  
Spindle  
Short spindle 
Short spindle 
Spindle  
Epithelioid  
N/A 
Epithelioid  
N/A 
N/A 
2:10 
10:10 
54:10 
1:10 
8:10 
14:10 
5:10 
8:10 
22:10 
16:10 
1:10 
5:10 
11:10 
1:10 
N/A 
14:10 
N/A 
N/A 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
wt 
N822K 
F681L 
None 
None 
None 
None 
N680K 
N680K 
None 
None 
None 
None 
S840N 
I571_D572delinsT 
N822K 
N822K 
N822K 
N822K 
1a 
1b 
2 
3a 
3b 
4a 
4b 
4c 
4d 
4e 
4f 
4g 
4h 
4i 
5a 
5b 
6a 
lower quad  
lower quad  
left lower quad preperitoneal fat 
left lower quad preperitoneal fat  
left lower quad preperitoneal far  
omentum  
omentum  
omentum  
omentum  
omentum  
omentum  
Omentum 
omentum  
omentum  
omentum  
omentum  
transverse colon nodule 
Mixed 
Mixed 
Mixed 
Mixed 
N/A 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Spindle  
Mixed 
N/A 
Mixed 
Mixed 
Mixed 
Mixed 
13:10 
15:10 
20:10 
05:10 
N/A 
00:05 
16:10 
14:10 
00:02 
03:05 
01:10 
17:10 
N/A 
00:03 
03:05 
07:10 
16:10 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
D816H 
None 
None 
None 
None 
None 
N680K  
None 
None 
None 
None 
Y646S  
None 
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6b 
7a 
7b 
8 
9 
10 
11a 
11b 
12a 
12b 
12c 
13 
14 
15 
16a 
16b 
17 
18 (NL) 
transverse colon nodule 
proximal small bowel mesnetery  
proximal small bowel mesnetery 
small bowel mesentery 
small bowel mesentery  
right colic gutter  
right colic gutter  
right colic gutter  
ileum 
ileum 
ileum 
small bowel mesntery nodule #4 
right colon mesenteric nodule 
left colic gutter 
pelvic deposits 
pelvic deposits 
rectosigmoid nodule 
ileum 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
N/A 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
15:10 
26:10 
10:10 
16:10 
07:10 
26:10 
N/A 
05:10 
03:10 
09:10 
10:10 
10:10 
02:04 
11:10 
08:10 
09:10 
09:10 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
None 
None 
D820E 
None 
None 
N655S 
N822H  
D820G 
None 
N822H  
D820A 
D820H  
N822K 
1 
2 
3a 
3b 
4a 
4b 
4c 
4d 
5a 
5b 
6a 
6b 
6c 
6d 
6e 
7a 
7b 
7c 
8 
left pelvis sigmoid epiploca 
right pelvic sidewall lesion 
right pelvic side wall peritoneum 
right pelvic side wall peritoneum 
right pelvic side wall nodules 
right pelvic side wall nodules 
right pelvic side wall nodules 
right pelvic side wall nodules 
colon serosal nodules 
colon serosal nodules 
left pelvic side wall nodules 
left pelvic side wall nodules 
left pelvic side wall nodules 
left pelvic side wall nodules 
left pelvic side wall nodules 
small bowel mesenteric nodule 
small bowel mesenteric nodule 
small bowel mesenteric nodule 
appendix 
Spindle  
mixed 
mixed 
Spindle  
Spindle  
Spindle  
mixed 
mixed 
Spindle  
mixed 
Spindle  
mixed 
mixed 
Spindle  
mixed 
Spindle  
mixed 
N/A 
mixed  
01:10 
17:10 
01:10 
02:10 
00:10 
00:10 
00:10 
00:10 
01:10 
05:10 
00:10 
00:10 
00:10 
00:10 
00:10 
00:10 
00:10 
00:10 
N/A 
Y553_Q556del 
Y553_Q556del 
Y553_Q556del 
Y553_Q556del 
Y553_Q556del 
Y553_Q556del 
V654A 
L783V 
V654A 
none 
None 
None 
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9 
10 
11 
12a  
12b 
12c 
12d 
13 (NL) 
cecal nodule 
mesial colon nodules 
peritoneal nodules 
perihepatic nodules 
perihepatic nodules 
perihepatic nodules 
perihepatic nodules 
small bowel 
mixed 
Spindle  
mixed 
Spindle  
mixed 
Spindle  
N/A 
02:10 
02:10 
00:10 
00:10 
00:10 
00:10 
00:10 
Y553_Q556del 
Y553_Q556del 
wt 
V654A 
None 
1a 
1b 
1c 
1d 
1e 
1f 
1g 
1h 
1i 
2 
3° 
3b 
4 
5 
6 
7 
8 
9a 
9b 
9c 
9d 
9e 
9f 
9g 
9h 
9i 
9l 
9m 
9n 
Omentum 
Omentum 
Omentum 
Omentum 
Omentum 
Omentum 
Omentum 
Omentum 
Omentum 
perivesicle fat 
sigmoid mass 
sigmoid mass 
Omentum 
Omentum 
transverse colon 
prox small bowel mesentery 
prox small bowel serosa 
mid small bowel mesenter 
mid small bowel mesenter 
mid small bowel mesenter 
mid small bowel mesenter 
mid small bowel mesenter 
mid small bowel mesenter 
mid small bowel mesenter 
mid small bowel mesenter 
mid small bowel mesenter 
mid small bowel mesenter 
mid small bowel mesenter 
mid small bowel mesenter 
mixed 
mixed 
mixed 
mixed 
mixed 
mixed 
N/A 
mixed 
mixed 
N/A 
mixed 
mixed 
N/A 
N/A 
mixed 
Epithelioid  
mixed 
mixed 
N/A 
mixed 
N/A 
N/A 
mixed 
mixed 
N/A 
mixed 
N/A 
mixed 
N/A 
09:10 
16:10 
09:10 
21:10 
35:10 
7:10 
0:10 
14:10 
8:10 
0:10 
21:10 
17:10 
N/A 
0:10 
0:10 
0:10 
0:10 
0:10 
0:10 
0:10 
0:10 
0:10 
0:10 
0:10 
0:10 
0:10 
0:10 
4:10 
0:10 
V559_E561del 
V559_E561del 
V559_E561del 
V559_E561del 
wt 
D820Y 
D820Y 
D820Y 
D820Y 
N822Y 
A829P 
A829P 
None 
D820Y 
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9o 
10 
11 
12 
13 
14 
15a 
15b 
15c 
15d 
15e 
15f 
15g 
16(NL) 
mid small bowel mesenter 
distal small bowel 
upper rectal mass 
lower rectal mass 
addition/al sigmoid nodule 
left colic gutter nodule 
sigmoid mesentery 
sigmoid mesentery 
sigmoid mesentery 
sigmoid mesentery 
sigmoid mesentery 
sigmoid mesentery 
spleen 
N/A 
mixed 
mixed 
mixed 
N/A 
N/A 
N/A 
N/A 
N/A 
mixed 
mixed 
mixed 
N/A 
0:10 
0:10 
5:10 
6:10 
0:10 
0:10 
0:10 
0:10 
0:10 
0:10 
0:10 
0:10 
0:10 
V559_E561del 
V559_E561del 
wt 
None 
D820G 
N822K 
1 
2 
3 
4 
5 
6a 
6b 
7 
8 
9 
10 
11 
12(NL) 
Adjacent to gallbladder 
Deep pelvis, near bladder 
Small bowel serosa 
Small bowel mesentery 
Small bowel mesentery 
Small bowel mesentery 
Small bowel mesentery 
Small bowel mesentery 
Small bowel mesentery 
Small bowel mesentery 
Small bowel mesentery 
Omentum 
Appendix 
mixed 
mixed 
mixed 
mixed 
mixed 
mixed 
mixed 
mixed 
mixed 
Epithelioid  
Epithelioid  
Epithelioid  
05:10
01:10
00:10
00:10
00:10
03:10
00:10
00:10
00:10
00:10
00:10
00:10
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
wt 
D820H 
1 
2a 
2b 
3 
Anterior peritoneal 
Left diaphragmatic mass 
Left diaphragmatic mass 
LUQ post (splenic flexure) 
Spindle  
mixed 
Spindle  
Spindle  
03:10
06:10
04:10
01:10
Delition in exon 11 
Delition in exon 11 
Delition in exon 11 
Delition in exon 11 
None  
Y823D  
Y823D 
V654A 
1 
2a 
2b 
3a 
3b 
left lower quadrant, abd wall 
small bowel 
small bowel 
midline abdomin/al wound 
midline abdomin/al wound 
Epithelioid  
mixed 
mixed 
N/A 
N/A 
03:10 
07:10 
05:10 
N/A 
N/A 
K642E 
K642E 
K642E 
V654A 
V654A 
V654A 
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4 
5 (NL) 
left upper quadrant 
small bowel 
N/A N/A 
1 
2a 
2b 
3a 
3b 
3c 
4 
5 
6 
6b 
6c 
7 
8 
9NL 
right lower quadrant 
right tumor nodule 
right tumor nodule 
mesentery 
mesentery 
mesentery 
mesenteric nodule 
mesenteric nodule 
sigmoid nodules 
sigmoid nodules 
sigmoid nodules 
right uterine nodule 
left pelvic side wall 
omentum 
Epithelioid  
Spindled  
Spindled  
mixed 
mixed 
mixed 
Spindled  
Spindled  
Spindled  
Spindled  
Spindled  
leiomyoma 
Spindled  
00:10 
00:10 
00:10 
05:10 
06:10 
05:10 
00:10 
00:10 
00:10 
00:10 
00:10 
n/a 
00:10 
Delition in exon 11 V654A 
1a 
1b 
1c 
1d 
2 
3a 
3b 
3c 
3d 
4 
5a 
5b 
6 
7 
8a 
8b 
9a (NL) 
9b(NL) 
9c(NL) 
mesentery  
mesentery  
mesentery  
mesentery  
mesentery  
omentum  
omentum  
omentum  
omentum  
mesentery 
Serosa 
Serosa 
mesentery  
uterus 
Mesentery 
Mesentery 
skeletal muscle 
omentum  
small bowel 
spindled 
N/A 
N/A 
N/A 
spindled 
spindled 
spindled 
spindled 
spindled 
adipe 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
N/A 
N/A 
N/A 
11:10 
N/A 
N/A 
N/A 
00:10 
00:10 
00:10 
00:10 
00:10 
n/a 
04:10 
00:10 
00:10 
00:10 
00:10 
00:10 
N/A 
N/A 
N/A 
W557R 
W557R 
W557R 
wt 
None 
None 
None 
None 
None 
None 
None 
1 
2 
Pelvic side wall 
Liver 
spindled 
N/A 
00:10 
N/A 
V559_Q575del 
V559_Q575del 
None 
V654A 
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3 
4(NL) 
Liver dome 
Liver 
spindled 00:10 V559_Q575del 
None 
1 
2 
3 (NL) 
Retroperitoneal 
spleen hilum 
spleen 
spindled 
spindled 
20:10 
00:10 
W557R 
W557R 
wt 
V654A 
1a 
1b 
1c 
1d 
2a 
2b 
3 
4a 
4b 
5a 
5b 
6a 
6b 
7a 
7b 
8a 
8b 
9 
10 
11a 
11b 
12a 
12b 
13 
14a 
14b 
15a 
15b 
16 
17 
18 
stomach/LUQ 
stomach/LUQ 
stomach/LUQ 
stomach/LUQ 
Ligament of trietz 
Ligament of trietz 
left mesocolon 
right lower quadrant 
right lower quadrant 
left rectus pelvis 
left rectus pelvis 
perivesical mass #1 
perivesical mass #1 
mesorectal mass #1 
mesorectal mass #1 
pelvic mass 
pelvic mass 
sigmoid nodule 
sigmoid mesentery nodule 
right perirectal tumor 
right perirectal tumor 
left pelvic sidewall nodule 
left pelvic sidewall nodule 
rectosigmoid serosal nodule 
right external iliac nodule 
right external iliac nodule 
deep rectal nodule 
deep rectal nodule 
right perivesical fat mass  
right perivesical fat mass  
left perivesical mass  
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
spindled 
30:10 
48:10 
30:10 
26:10 
<1:10 
<1:10 
00:10 
50:10 
40:10 
42:10 
40:10 
32:10 
57:10 
30:10 
27:10 
40:10 
13:10 
0:10 
14:10 
0:10 
40:10 
0:10 
12:10 
56:10 
14:10 
2:10 
20:10 
0:10 
0:10 
20:10 
12:10 
V559_E561del 
V559_E561del 
V559_E561del 
V559_E561del 
A829P 
None 
A829P 
A829P 
A829P 
A829P 
A829P 
A829P 
None 
None 
A829P 
V654A 
V654 
A829P 
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19 
20 (NL) 
ileocecal nodule 
gastric mucosa 
spindled 0:10 
wt 
1a 
1b 
1c 
1d 
2 (NL) 
mesentery 
mesentery 
mesentery 
mesentery 
small intestine 
spindled 
spindled 
spindled 
spindled 
57:10 
68:10 
65:10 
50:10 
N564_Y578del 
wt 
None 
1a 1a 
1b 1b 
1c 1c 
2 2 
3 (NL) 3 (NL) 
midline pelvic 
midline pelvic 
midline pelvic 
small bowel mesenteric 
Gallbladder 
spindled 
spindled 
spindled 
spindled 
0:10 
4:10 
0:10 
1:10 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 
A502_Y503dup 

None 
None 
None 
None 
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Heterogeneity of kinase inhibitor resistance mechanisms within and between different GIST 
metastases in a given patient 
Primary KIT mutations were found in all the samples analyzed but not in the normal tissues from 
the same patients. In all the tumor samples corresponding to single patient, the same primary 
mutation was detected. 
These secondary mutations were clustered mainly in three regions of the KIT oncoprotein: the 
juxtamembrane domain (encoded by exon 11), the TKD 1 (tyrosin kinase domain 1, encoded by 
exons 13 and 14) and the TKD 2 (tyrosin kinase domain 2, encoded by exons 17 and 18). 
Nucleotide changes impacted three residues, D816, D820 and N822, and led to 2-4 alternative 
amino acid substitutions each - D816H/G, D820E/G/Y/A and N822K/Y/H. 2 small del/ins outside 
the kinase domain were detected: a 6-nucleotide deletion in exon 11 resulting in Q575_P57delinsH, 
and a 3-nucleotide deletion combined with a nucleotide substitution resulting in I571_D572delinsT. 
In total, 6 of the secondary KIT mutations detected were novel mutations (I571_D572delinsT, 
Q575_P577delinsH, N655S, N680K, F681L and S840N).  
Up to 7 TKI resistance mutations in different progressing metastases from a typical multifocal 
progressing patient  
In patient # 1, 46 metastases (52 samples) had an insertion of 6-bp in KIT exon 9 that resulted in a 
tandem repeat of AY502_503 in the extracellular juxtamembrane region, the most common exon 9 
mutation described in GIST. 7 different predominant secondary KIT mutations - I571_D572delinsT, 
Q575_P577delinsH, N655S, N680K, F681L, N822K and S840N - were identified at the genomic 
level. In GIST  exon 11 and an exon 9 mutations appear to be mutually exclusive.  
Among the 52 GISTs from this patient, the cellular morphology ranged from typical spindle cell to 
epithelioid; spindle cell were characterized by eosinophilic fibrillary cytoplasm. GISTs with 
epithelioid morphology were composed of round cells with eosinophilic to clear cytoplasm, 
arranged in sheets and nests. Express and activation of KIT was evaluated in frozen metastatic 
GIST lesions from the same patient, showing consistent expression level of KIT. These results 
illustrate the remarkable heterogeneity of progressing GISTs lesion from a single, multifocal 
progressing patient. 
Functional studies 
To better understand whether these novel mutations could be involved in the mechanism of 
acquired resistance, secondary mutations of interest were engineered into KIT constructs, on their 
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own and in combination with the primary mutation. Transient transfection experiments in 
HEK293T cells and in GIST48B (that usually do not express KIT , except with a construct) with the  
variant KIT constructs were performed. The inhibition of KIT phosphorylation was examined using  
different concentrations of imatinib or sunitinib. Phosphorylated KIT corresponds to activated KIT  
tyrosine kinase. In our experimental system, a representative KIT exon 11 mutation (V560D) 
construct, sensitive to both imatinib and 
sunitinib, served as negative control (Figure 
20) while the N822K mutation, known to 
confer resistance to imatinib and sunitinib, 
was used as a positive control.  
The primary KIT A502_Y503dup mutation 
alone was resistant to imatinib and sensitive 
to sunitinib (Figure 20). I571_D572delinsT, 
Q575_P577delinsH, N655S, N680K, F681L 
and S840N resulted in sunitinib resistance, 
either in isolation or when co-expressed with 
KIT A502_Y503dup (Figure 21). The 
secondary KIT mutants tested showed 
resistance to sunitinib in vitro, providing 
strong evidence that each of these mutations plays a causal role in the clinical resistance to 
sunitinib. 
  
Figure 20. Immunoblot analysis of HEK293 cells transfected with mutant KIT constructs with primary mutation 
(A502_Y503duplication or V560D) and exposed to various doses of imatinib and  sunitinib.
Figure 21. I571_D572delinsT and Q575_P577delinsH 
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
Figure 23 Immunoblot analysis of HEK293 cells transfected with mutant KIT constructs with S840N and exposed to various doses 
of imatinib, sunitinib. 

The isolated KIT A502_Y503dup mutation was resistant to imatinib and sensitive to sunitinib 
(Figure 20), in keeping with the role of KIT exon 9 mutations in imatinib resistance. Interestingly, 
secondary sunitinib-resistant KIT mutations - I571_D572delinsT and Q575_P577delinsH - result in 
imatinib response when co-expressed with KIT A502_Y503dup (Figure 21). 
These studies provide a rigorous evaluation of known and novel TKI genomic resistance 
mechanisms in GIST. We show that the molecular drug-resistance mechanisms can be defined in 
94% of progressing GISTs after imatinib and/or sunitinib therapies. Novel TKI resistance mutations 
in the juxtamembrane region, TKD 1, and TKD 2 of KIT have been identified. We demonstrates the 
heterogeneity of molecular drug-resistant mechanisms, between different clinically-progressing 
metastases, in each patient with clinically progressing GIST after initial response to imatinib and/or
sunitinib. 
Figure 22. Immunoblot analysis of HEK293 cells transfected with mutant KIT constructs and exposed to various doses of 
imatinib and  sunitinib.
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The juxtamembrane region KIT mutation (exon 11) is the most common mutation type in GIST, and 
mutation of codon 559 and/or codon 560 is often observed. These types of mutations are sensitive 
to both imatinib and sunitinib. The two juxtamembrane region KIT mutations (I571_D572delinsT, 
Q575_P577delinsH) reported here are unique. A502_Y503dup mutation was partially resistant to 
imatinib and sensitive to sunitinib. I571_D572delinsT and Q575_P577delinsH resulted in strong 
sunitinib resistance. These results show that different mutations, even within the same 
juxtamembrane domain of KIT show different inhibitory effects on TKIs.  
S840N has been previously published as a presumptive non-oncogenic mutation, in a single case 
report (132). This S840N mutation was reported as a germline finding in a 2-year-old child with 
cutaneous mastocytosis. The child’s father carried the same germline S840N, therefore the authors 
concluded the S840N was irrelevant. Interestingly, somatic S840N substitution was found in 29% 
of GIST metastases from patient 1. The S840N causes definite shift in sunitinib-sensitivity in our 
functional assay.  
Discussion 
The aim of this study was to understand better the TKI genomic resistance mechanisms in GIST and 
the relationship between kind of mutation and drug resistance. 
We showed that the molecular drug-resistance mechanisms can be identified in more than 90% of 
GISTs progressing under imatinib and/or sunitinib irrespective of whether the primary mutation was 
in exon 9 or 11; the most common primary mutation in GIST is located in the justmembrane region 
codified by exon 11 and mutation at the codon 559 and 560 and the duplication A502_Y503 is often 
observed. the mutation at codons 559 and 560 are sensitive to both imatinib and sunitinib; 
A502_Y503dup is partially resistant to imatinib and sensitive to sunitinib. 
The secondary mutations were clustered in ATP binding pocket and in the activation loop of the 
kinase domain. 
The results showed that two or more (to up to 7) TKI-resistance mutation can be present in the same 
patient; in particular, patient 1 had up to seven different mutations. 
We identified 6 novel mutations (2 deletion/insertions, I571_D572delinsT and Q575_P577delinsH, 
and 4 substitutions, N655S, N680K, F681L and S840N). To evaluate if these mutation were 
involved in secondary resistance acquisition, we used we engineered these into KIT construct, alone  
and in combination with a primary mutation. N822K, known to confer resistance to imatinib and 
sunitinib, was used as positive control. 
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I571_D572delinsT and Q575_P577delinsH are unique; these two mutations resulted in strong 
sunitinib resistance but resulted in imatinib response when co-expressed with A502_Y503dup. 
These results show that different mutations, even within the same juxtmemembrane domain of KIT 
display different effect of TKIs. 
N655S, N680K, F681L and S840N were tested. All the mutations resulted involved in resistance 
acquisition. 
KRAS and KIT gatekeeper mutations and primary imatinib resistance in GIST: relevance of 
concomitant PI3K/AKT dysregulation 
Approximately 10% of GIST patients have primary imatinib resistance, defined by clinical 
progression within three to six months after initiating therapy. Such GISTs typically lack KIT and 
PDGFRA mutations, or contain particular mutations, e.g. PDGFRA D842V, that are intrinsically 
imatinib resistant. Our study found for the first time polyclonal heterogeneity as a mechanism of 
primary imatinib resistance in a GIST patient. 
A 61-year-old man presented to an outpatient clinic in October 2003 with an 8-week-history of 
progressive left shoulder pain, nausea and fatigue. Abdominal CT-scan revealed a 19.7 x 13.1 cm 
mass arising from the anterior wall of the stomach, accompanied by five liver metastases, all less 
than 1 cm in maximal diameter. Endoscopic biopsy demonstrated a spindle cell GIST with 20 
mitoses per 50 hpf. 
The patient received imatinib 400 mg per day and got improvement within one month (resolution of 
shoulder pain, softening of the palpable mass and normalization of the blood counts). CT-scan after 
six weeks of imatinib showed that the gastric mass had typical post-therapy changes, hypodensity as 
well as decrease in wall thickness. The liver metastases were not changed. CT-scan after 16 weeks 
from imatinib treatment beginning displayed reduction of the hypodense gastric residual mass 
however, a new hyperdense 2.7 x 2.0 cm nodule appeared at the caudal aspect of the mass. The 
patient remained under imatinib, and a follow-up CT-scan two months later showed progression of 
the hyperdense nodule to 4.9 x 5.6 cm, now accompanied by new progressing nodules. An upper 
gastrointestinal bleed caused the resection of the gastric mass, performed 24 hours after the last 
imatinib dose. Histologically, the gastric mass was spindle cell-type GIST. Genomic analyses by 
Sanger sequencing, Ion Torrent and Sequenom. were performed in clinically responding (region 1) 
vs clinically progressing (regions 2 and 3) aspects of the mass: region 1 was non-mitotic, and 
consistent with sTable/responding disease, whereas regions 2 and 3 had 60 and 55 mitoses per 50 
hpf, respectively, and were therefore consistent with progressing, imatinib-resistant, disease. Each 
of these three regions expressed KIT strongly, with a homozygous KIT exon 11 E554_V559del 
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mutation (Figure 27A) and a homozygous PTEN missense mutation, C124S (Figure 27B). The 
imatinib-responsive region 1 had no additional mutations, whereas imatinib resistant region 2 had a 
KRAS G12R 

Figure 27.  The three regions showed a KIT E554_V559del (27A), a PTEN missense mutation(27B). The region 2 (imatinib-
resistant) had a KRAS G12R mutation (27C) and the region 3 (imatinib-resistant) had a 
KIT T670I mutation (27D).
mutation by Sequenom analysis, which was subsequently 
confirmed through genomic sequencing (Figure 27C). Imatinib-
resistant region 3 had a KIT “gatekeeper” T670I mutation (Figure 
27D), which is known to confer imatinib resistance. 
Western-blotting experiments confirmed strong KIT expression in 
both imatinib-responsive and resistant regions (Figure 28); 
however, KIT was activated, as disclosed by phosphoKIT Y721 
expression, only in region 3 with the KIT T670I mutation, MAPK 
was hyperactivated only in the region 2 with KRAS G12R, 
whereas AKT and S6 were hyperactivated in both of regions 
(Figure 28). 
Imatinib was resumed, but the patient experienced progression of 
intra-abdominal disease, and died five months later, while 
receiving high-dose imatinib (800 mg/day). He did not receive 
sunitinib, as it was not yet approved by FDA for imatinib resistant 
Figure 28. Results for western blotting 
showed KIT was activated only in 
region 3 with the KIT T670I mutation, 
MAPK was hyperactivated only in the 
region 2 with KRAS G12R, and AKT 
and S6 were hyperactivated in both of 
these regions.
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GIST.  ISTs lacking KIT and PDGFRA mutations frequently have primary imatinib-resistance, and 
often they do not have known mutations. To test the hypothesis that such GISTs might contain RAS 
mutations or other KIT-downstream mutations, we used a Sequenom panel to screen for RAS, BRAF 
and PI3KCA mutations in KIT/PDGFRA-wildtype GISTs from 27 patients. Only one of 27 GISTs 
contained demonstrable mutations: this was a high-risk GIST (62 mitoses per 50 hpf) that contained 
both HRAS G12V and PIK3CA H1047R mutations. PIK3CA H1047R is a gain-of-function 
mutation that accounts for ~20% of PIK3CA mutations in advanced human cancers and is 
associated with response to PI3K/AKT/mTOR pathway inhibitors [133]. 
Discussion 
This brief report represents the first evidence of primary imatinib resistance resulting from 
intratumoral genomic heterogeneity. This resistance, already at 16 weeks of treatment, was related 
(in separate lesions) to KRAS mutation and the KIT gatekeeper mutation T670I. Recently, in vitro 
evidence that KRAS mutations might confer imatinib resistance in GIST has been reported [134] 
and this case seems to confirm that KRAS gain-of-function mutation contributes to clinical imatinib 
resistance, in spite of therapeutic KIT oncoprotein inhibition. It is thinkable that KRAS mutations 
are present as minor subclones in more untreated GISTs than previously appreciated, and are then 
enriched for by KIT/PDGFRA-inhibitor therapies. 
Conclusion
In conclusion, these novel findings demonstrate KRAS mutation and polyclonal heterogeneity as 
mechanisms of primary imatinib resistance in GIST, show that both KRAS and HRAS isoforms can 
contribute to GIST oncogenesis, and highlight the conjoined nature of the PI3K/AKT and 
RAS/RAF signaling pathways in GIST tumorigenesis. These findings validate the 
PI3K/AKT/mTOR and RAS/RAF/MEK pathways as concurrently relevant in GIST oncogenic  
signaling. 
Discussion and Conclusions
69
Discussion and Conclusions 
Clinical diseases represent complex biological phenotypes reflecting the interaction of a myriad of 
genetic and environmental contributions. 
To the best of our knowledge, this is the first work that consider the pharmacological response in 
GIST patients treated with imatinib by two different angles: the genetic and somatic point of view. 
We first analyzed the influence of polymorphisms on treatment outcome, keeping in consideration 
SNPs in genes involved in the drug transport, metabolism and folate pathway. 
Using a multiple candidate gene approach, we found that SLC22A4 rs1050152 was significantly 
associated with a reduced TTP. To us this finding seems very promising, as we found the same 
polymorphism correlating with the major molecular response rate in a set of CML patients [79], 
indicating that imatinib delivery could be really affected by this allelic variant. We also analyzed 
polymorphisms in three genes – SLCO1A2, SLC22A5 and ABCC4 for the first time and we 
identified the minor allele for SLC22A5 rs2631367 and rs2631372 associated with a prolonged 
TTP. The correlation between SNPs in members of OCTN family transporters and imatinib efficacy 
could be very important in relation to the use of imatinib in the adjuvant setting. 
On the other hand, we found that polymorphism in RFC and FOLR genes may be associated with 
TTP; to us this finding is intriguing, as both the genes products are involved in the folic acid and 
reduced folates uptake.  
Naturally, all these intriguing results cannot be considered as the only main mechanism in imatinib 
response. GIST mainly depends by oncogenic gain of function mutations in tyrosin kinase receptor 
genes, KIT or PDGFRA, and the mutational status of these two genes or acquisition of secondary 
mutation is considered the main player in GIST development and progression. To this purpose we 
analyzed the secondary mutations to better understand how these are involved in imatinib 
resistance. In our analysis we considered both imatinib and the second line treatment, sunitinib, in a 
subset of progressive patients. 
We identified in particular 6 novel mutations and on the basis of functional studies we certainly 
concluded that all these variations were involved in resistance acquisition. 
In general, in GIST there is a main primary mutation in exon 9 or 11, mutually exclusive; the 
secondary mutation does not depend by the first one and it is possible that more than 2 secondary 
mutations (from 2 to 7) occur in the same patient. 
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For the first time we demonstrated that primary imatinib resistance could result from genomic 
heterogeneity. In the case here described the resistance was related to KIT and KRAS mutations, 
validating the hypothesis that PI3K/AKT/mTOR and RAS/RAF/MEK pathways are concurrently 
relevant in GIST oncogenic signaling and responsible for GIST progression. 
KIT/PDGFRA mutation analysis is an important tool for physicians, as specific mutations may 
guide therapeutic choices. Currently, the only adaptations in treatment strategy include imatinib 
starting dose of 800 mg/daily in KIT exon-9-mutated GISTs. In addition, the primary resistance of 
PDGFRA D842V GISTs which leads to the lack of rationale for the use of imatinib in these 
patients. 
In the attempt to individualize treatment, genetic polymorphisms represent a novelty in the 
definition of biomarkers of imatinib response in addition to the use of tumor genotype. 
Accumulating data indicate a contributing role of pharmacokinetics in imatinib efficacy, as well as 
initial response, time to progression and acquired resistance.  At the same time it is becoming  
evident that genetic host factors may contribute to the observed pharmacokinetic inter-patient 
variability. Genetic polymorphisms in transporters – some of which are already known as causes of 
drug resistance in cancer chemotherapy – and in metabolizing genes may affect the activity or 
stability of the encoded enzymes. Thus, integrating pharmacogenetic data of imatinib transporters 
and metabolizing genes, whose interplay has yet to be fully unraveled, has the potential to provide 
further insight into imatinib response/resistance mechanisms. In view of these considerations, 
collecting data on the role of polymorphisms in imatinib response in GISTs represents a clinical 
priority. 
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Future perspectives: ongoing studies 
I. DNA repair polymorphisms in GIST: susceptibility and correlation 
with tumor characteristic and clinical outcome.
II. VEGF pathway genes polymorphisms in GIST patients in treatment 
with sunitinib after imatinib failure.
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I. DNA repair polymorphisms in GIST: susceptibility and correlation with 
tumor characteristic and clinical outcome. 
DNA repair pathway - During life, DNA accumulates changes that activate proto-oncogenes and 
inactivate tumor soppresor genes. The genetic instability drives the tumorigenesis and is fuelled by 
DNA damage and errors made by DNA repair machinery. Figure 29 summarizes some of the most 
common types of DNA damages and their causes [135].

Figure 29. DNA damage, repair mechanisms (A) and consequences (B).
The main DNA repair pathways in humans are direct reversal, base and nucleotide excision, 
mismatch, homologous recombination repair, and non-homologous end joining [136]. When 
proteins/enzymes products of these pathways fail to repair damage because of a functional 
deficiency, the cell accumulates DNA damage and induces apoptosis. Alternatively, unrepaired 
damage may enhance mutation, including chromosomal aberrations that can in turn alter apoptotic 
signals, dysregulate cell growth, and induce carcinogenesis. Therefore, it has been hypothesized that 
germline or somatic variations, such as polymorphisms of DNA repair-related genes play an 
important role in the risk of cancer development [137,138]. 
On the basis of these evidences, we decided to analyze a panel of SNPs in the main genes involved 
in the different DNA repair pathways.  
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Study population - A total of 60 unresectable/metastatic GIST patients were retrospectively enrolled 
in this study. These patients are the same described in the “folate” study. 
Genotyping analysis - We selected twenty common [minor allele frequency (MAF) > 0.05 in 
Caucasian], well-studied functional variants - located in regulatory region, cause non-synonymous 
amino acid changes and/or have been repeatedly associated with cancer risk, survival or treatment 
response. Characteristics of the studied polymorphisms - all single nucleotide polymorphisms - are 
reported in Table 15. Genotypes were determined by PCR based assays (i.e. RFLP and RT). 
Positive and negative controls were included in each reaction as quality control. In addition, for 
internal quality control (accuracy of genotyping) 90% of samples were repeated. The concordance 
between the original and the duplicate samples for all the analysed polymorphisms was 100%. 
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Statistical analysis - The distribution of genotypes was tested for departures from the Hardy-
Weinberg equilibrium using the χ2 test. Survival analysis methods were used to examine the 
relationship between genotypes [homozygous wild-type, heterozygous and homozygous for the 
variant allele] and GIST time to progression. In univariate analysis, the survival curves were 
estimated and plotted with the Kaplan-Meier method. The curves were compared with log-rank test 
Table 15. SNPs description 
Gene [full name; Protein name]   SNP ID METHOD [A]  
APEX [apurinic/apyrimidinic endonuclease 1 ] 
rs1130409 [Asp148Glu] RT TaqMan assay 
XPD [Xeroderma pigmentosus gruup D] / ERCC2[Excision repair cross-complementation group 2] 
rs1799793 [Asp312Asn] 
rs13181[Lys751Gln] 
RT TaqMan assay  
RFLP [ 
hOGG1[ Human 8-oxoguanine DNA glycosylase 1] 
rs1052133 [Ser326Cys] RT TaqMan assay  
XRCC1 [X-ray repair cross-complementing group 1] 
rs1799782 [Arg194Trp]] RT TaqMan assay c__11463404_10 
rs25487 [Arg399Gln] RFLP [] 
100
XRCC3 [ X-ray repair cross-complementing group 3] 
rs861539 [Thr241Met] RT TaqMan assay C_12005959_10
NBS1 [Nijmegen breakage syndrome]
rs1801394 [Ile49Met] RT TaqMan assay C_3068176_10 
XPA [Xeroderma pigmentosus gruup A] 
rs1800975 [??4G>A ] 
rs2808668 [Intronic] 
RT TaqMan assay C___482935_1_ 
RT TaqMan assay C__9312100_10 
XPC [Xeroderma pigmentosus gruup C] 
rs2228000 [Ala499Val] RT TaqMan assay C__16018061_10
rs2228001 [Gln939Val] RT TaqMan assay C___234281_1_ 
XPF [Xeroderma pigmentosus gruup F ] 
rs18000267 [Gln415Arg] 
rs3136155 [Intronic] 
RT TaqMan assay C___3285104_10 
RT TaqMan assay C__26942939_10 
XPG [Xeroderma pigmentosus gruup G] 
rs17655 [Asp1104His] 
rs2094258 [5’UTR] 
RT TaqMan assay C__1891743_10 
RT TaqMan assay C___1891783_10 
[A] RT = Real-Time PCR with TaqMan allelic discrimination assay [Applera, Foster City, USA]; 
    RFLP = PCR-RFLP, analysis carried out according to published methods [reference 
parenthetically]. 
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of equality of survivor functions (statistical significance defined as P < 0.05). In multivariate 
analysis, hazard ratios (HR) and 95% confidence interval (95% CI) were estimated with Cox 
proportional hazards models, using gender, age, and status (localised/metastatic) at diagnosis, as 
covariates in addition to the genotype. The proportional hazards assumption was tested (P > 0.05) 
using Schoenfeld residuals. Multiple logistic regression was used to assess the relation between 
individual polymorphisms and primary resistance. Statistical analysis was conducted using Stata 
Intercooled version 12.0. 
The analysis is ongoing, partially completed. 
II. VEGF pathway genes polymorphisms in GIST patients in treatment with 
sunitinib after imatinib failure.
VEGF pathway - The VEGF pathway play a central role in angiogenesis throughout the tumor 
development. The production of VEGF is stimulated by upstream activators, including 
environmental cues, growth factors, oncogenes, cytokines, and hormones. The binding of VEGF to 
its receptors on the surface of endothelial cells activates intracellular tyrosine kinase, triggering 
multiple downstream signal that promote angiogenesis. Although there are multiple variants of 
VEGF and its receptors, the angiogenic effects of this pathway are primarily mediated through the 
VEGFA (the most common variant) with VEGFR-2 (Figure 30) [139-141]. 
As previously described, currently, the only approved second-line drug is sunitinib malate - a 
multitargeted agent, an inhibitor of tyrosine kinase, of KIT and PDGFRA/B and of the VEGFRs -1, 
-2 and 3, FMS-like tyrosine kinase-3, colony stimulating factor 1 receptor, and glial cell-line 
derived neurotrophic factor receptor (REarranged during Transfection; RET) [48]. 
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Figure 30. Main players in VEGF pathway: 1) Upstream activators stimulate the production of VEGF; 2) VEGF bind to receptors of 
endothelial cells; 3) angiogenesis is mediated primarily through the interaction of VEGF and VEGFR-2; 3) other variants of VEGF 
and its receptors play a secondary role in this process.
The aim of this analysis is to evaluate factors predicting results of sunitinib second-line therapy in 
inoperable/metastatic GISTs. We want to investigate the impact of the selected SNPs in VEGFA
and VEGFR-1, 2, 3 genes on sunitinib-response in a group of GIST patients. 
Study population - A total of 43 unresectable/metastatic GIST patients were retrospectively enrolled 
in this study in 2013 and 2014 at the Sant’Orsola-Malpighi Hospital, Bologna. All patients were 
under sunitinib as second line treatment, after imatinib failure. Overall survival (OS) was defined as 
the time from the first day of treatment to death from disease. Dates of death were obtained and 
cross-checked using the inpatient medical records. If a patient was alive, OS were censored at the 
time of the last follow-up. Data for patients who did not progressed at the last follow-up TTP 
evaluation were censored at that time.  
In order to exclude disease susceptibility we also genotyped 184 controls, anonymous blood donors 
from the Centro Trasfusionale, Sant’Orsola-Malpighi Hospital, Bologna. The study was approved 
by the Ethics Committees of the institution. The analysis was done after written informed consent 
for study participation and anonymous data publication in accordance with national legislation. Any 
subjects could cancel participation at any time during the study, according to Helsinki Declaration 
and later Amendments. 
Genotyping analysis - We selected nineteen common [minor allele frequency (MAF) > 0.05 in 
Caucasian] well-studied functional variants - located in regulatory region of four genes involved in 
VEGF pathway. Patients with available peripheral blood were eligible for this retrospective study. 
DNA was isolated as previously described. Characteristics of the studied polymorphisms - all single 
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nucleotide polymorphisms - are reported in Table 16. Genotypes were determined by RT-PCR as 
previously described. Positive and negative controls were included in each reaction as quality 
control. In addition, for internal quality control (accuracy of genotyping) 90% of samples were 
repeated. The concordance between the original and the duplicate samples for all the analysed 
polymorphisms was 100%.
Statistical analysis – as previously described, the distribution of genotypes was tested for departures 
from the Hardy-Weinberg equilibrium using the χ2 test. Survival analysis methods were used to 
examine the relationship between genotypes [homozygous wild-type, heterozygous and 
homozygous for the variant allele] and GIST time to progression. In univariate analysis, the survival 
Table 16. SNPs description 
Gene [full name; Protein name]   SNP ID METHOD [A]  
VEGFA [Vascular endothelial growth factor A] 
rs699947 [Intronic] 
rs833061 [Intronic] 
rs2010963 [5’UTR] 
rs3025039 [3’UTR] 
RT TaqMan assay C___8311602_10 
RT TaqMan assay C___1647381_10 
RT TaqMan assay C___8311614_10 
RT TaqMan assay C___16198794_10 
VGFR1[Vascular Endothelial Growth Factor Receptor 1] 
rs9513070 [Intronic] 
rs9554320 [Intronic] 
rs9554319 [Intronic] 
rs9554316 [Intronic] 
rs9582036 [Intronic] 
RT TaqMan assay C__30362252_10 
RT TaqMan assay C__32231227_10 
RT TaqMan assay C__1910659_10 
RT TaqMan assay C__32231224_10 
RT TaqMan assay C__1910658_10 
VGFR2[Vascular Endothelial Growth Factor Receptor 2] 
rs1531289 [Intronic] 
rs1870377 [Gln472His] 
RT TaqMan assay C__7439188_20 
RT TaqMan assay C__11895315_20 
rs2305948 [Ile297Val] 
rs11133360 [Intronic] 
rs6828477 [Intronic] 
RT TaqMan assay C__22271999_20 
RT TaqMan assay C__26111278_10 
RT TaqMan assay C__1673866_10 
rs6837735 [Intronic] RT TaqMan assay C__30784758_10 
VGFR3[Vascular Endothelial Growth Factor Receptor 3] 
rs307805 [[Intronic] 
rs307822 [3’UTR] 
RT TaqMan assay C__918880_10 
RT TaqMan assay C___988831_1 
rs6877011 [3’UTR] 
rs7709359 [Intronic] 
RT TaqMan assay C__29057584_10 
RT TaqMan assay C__30240676_10 
[A] RT = Real-Time PCR with TaqMan allelic discrimination assay [Applera, Foster City, USA]; 
    RFLP = PCR-RFLP, analysis carried out according to published methods [reference 
parenthetically]  
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curves were estimated and plotted with the Kaplan-Meier method. The curves were compared with 
log-rank test of equality of survivor functions (statistical significance defined as p < 0.05). In 
multivariate analysis, hazard ratios (HR) and 95% confidence interval (95% CI) were estimated 
with Cox proportional hazards models, using gender, age, and status (localised/metastatic) at 
diagnosis, as covariates in addition to the genotype. The proportional hazards assumption was tested 
(P > 0.05) using Schoenfeld residuals. Multiple logistic regression was used to assess the relation 
between individual polymorphisms and primary resistance. Statistical analysis was conducted using 
Stata Intercooled version 12.0. 
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